Pharmaceutical composition for preventing or treating Parkinson's disease or non-alcoholic steatohepatitis

By developing novel pyrimidine derivatives with MLK3 and LRRK2 inhibitory activities, the problem of insufficient inhibitory activity of these enzymes in the prior art has been solved, and cancer, viral infectious diseases, Parkinson's disease, and non-alcoholic steatohepatitis has been achieved. and effective treatment of tuberculosis.

CN118976029APending Publication Date: 2024-11-19KOREA RES INST OF CHEM TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411012417.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-12-16
Filing Date
2020-12-16
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art lacks effective inhibitory activity of pyrimidine derivatives on mixed lineage kinase 3 (MLK3) and leucine-rich repeat kinase 2 (LRRK2) and cannot effectively prevent or treat cancer, viral infectious diseases, Parkinson's disease, Non-alcoholic steatohepatitis and tuberculosis.

Method used

A novel pyrimidine derivative has been developed with significant MLK3 inhibitory activity and LRRK2 inhibitory activity, and by specific chemical structure design, a pharmaceutically acceptable salt or complex is formed for the preparation of pharmaceutical compositions to prevent or treat the above-mentioned disease.

Benefits of technology

This novel pyrimidine derivative composition can effectively inhibit the activity of MLK3 and LRRK2, thereby preventing or treating cancer, viral infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis and tuberculosis, providing a new therapeutic strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004964768880000041
    Figure BDA0004964768880000041
  • Figure BDA0004964768880000051
    Figure BDA0004964768880000051
  • Figure BDA0004964768880000052
    Figure BDA0004964768880000052
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease or non-alcoholic steatohepatitis, said pharmaceutical composition having excellent MLK3 inhibitory activity and LRRK2 inhibitory activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease or non-alcoholic steatohepatitis, and more specifically, to a pharmaceutical composition for preventing or treating Parkinson's disease or non-alcoholic steatohepatitis comprising a mixed lineage kinase 3 (MLK3) inhibitory activity and a leucine-rich repeat kinase 2 (LRRK2) inhibitory activity. Background Art

[0002] Protein kinases are enzymes that catalyze the transfer of the terminal phosphate group of adenosine triphosphate (ATP) to specific residues (tyrosine, serine, threonine) of proteins and are involved in regulating signals of cell activity, growth and differentiation in response to changes in the extracellular medium and environment.

[0003] Generally, protein kinases are divided into serine and / or threonine kinase groups and tyrosine kinase groups according to their phosphorylated substrates (Hanks, SK et al., FASEB J., 9 (8), 576-596, 1995). The serine / threonine kinase group includes protein kinase C isoforms (Newton, AC, J Biol Chem., 270 (48), 28495-28498, 1995), cyclin-dependent kinases group and cdc2 (Pines, J., Trends Biochem Sci., 18 (6), 197, 1993). The tyrosine kinase components are transmembrane growth factor receptors (including epidermal growth factor receptor) (Iwashita, S. et al., Cell Sig Nal., 4 (2), 123-132, 1992), cytoplasmic non-receptor kinases (including p56tck, p59fYn, ZAP-70) and C-terminal Src kinase (Chan, AC et al., Annu Rev Immunol., 12, 555-592, 1994).

[0004] Abnormally elevated protein kinase activity is directly or indirectly associated with many diseases caused by abnormal cellular action. For example, diseases can be caused by the failure of appropriate regulatory mechanisms of kinases associated with mutations, overexpression, or abnormal enzyme activity; or by excess or deficiency of cytokines or factors involved in upstream or downstream signal transduction of kinases. Therefore, selective inhibition of kinase activity can be a useful target for the development of new drugs for the treatment of diseases.

[0005] Mixed lineage kinase 3 (MLK3) is a member of the mixed lineage kinase (MLK) family that can regulate mitogen-activated protein kinases (MAP kinases) (especially c-Jun amino-terminal kinase (JNK)) that play important roles in cancer cell proliferation and survival using various signal transduction systems.

[0006] In addition, many studies have recently been conducted to develop compounds that inhibit the enzymatic activity of MLK3 for use as therapeutic agents for cancer, viral infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, etc. (Chadee, DN, Can J Physiol Pharmacol., 91(4), 268-274, 2013; Ratta Nasinchai, C. et al., Cancers (Basel)., 8(5), 51, 2016; Xu, H. et al., J Virol., 93(18), e00758-19, 2019; Sami Nathan, P. et al., J Neuroimmune Pharmacol., 14(1), 44-51, 2019; Goodfellow, V Set al., J Med Chem., 56(20), 8032-8048, 2013; Jiang, JX et al., Livermore Int., 34(8), 1131-1132, 2014; Tomita, K. et al., JCI Insight., 2(15), 94488, 2017; Ibrahim, SHet al., LiverInt., 34(3), 427-437, 2014; Parkinson Study Group PRECEPT Investigators, Neurology, 69(15), 1480-1490, 2007; Kline, EM et al., Exp Neurol., 318, 157-164, 2019).

[0007] Leucine-rich repeat kinase 2 (LRRK2) is a protein belonging to the leucine-rich repeat kinase family, composed of 2527 amino acids with high similarity between species, and characterized by having both guanosine triphosphate (GTP) hydrolase (GTPase) and serine-threonine kinase activities in one protein. LRRK2 expression has been observed in various organs and tissues including the brain, and at the cellular level, it is known to exist in the cytoplasm or cell membrane and mitochondrial outer membrane. Currently, the precise in vivo functions of LRRK2 are being actively studied. Since it has five functionally important domains, it is expected to have self-activity regulation based on autophosphorylation and cellular function regulation through protein interaction and enzyme action. In particular, it is known that the chaperone machinery, cytoskeletal arrangement, protein translation machinery, synaptic vesicle endocytosis, mitogen-activated protein kinases signaling cascades, and ubiquitin / autophage protein degradation pathways are regulated by LRRK2.

[0008] In addition, the enzymatic activity of LRRK2 has been reported in multiple existing papers (Liu, Z. et al., Biochim Biophys Acta Proteins Proteom., 1865(3), 274-280, 2017; Herbst, S. et al., ACS Infect Dis., 5(6), 809-815, 2019; Hartlova, A. et al., EMBO J., 37(12), e98694, 2018).

[0009] On the other hand, as existing documents related to compositions for preventing or treating cancer, viral infectious diseases, Parkinson's disease, non-alcoholic fatty liver disease and tuberculosis containing pyrimidine derivatives as active ingredients, Korean Patent No. 10-0832602 discloses a novel polycyclic compound related to MLK3 enzyme activity and its use, Korean Patent No. 10-1876514 discloses a novel pyrimidine compound and a pharmaceutical composition for preventing or treating cancer containing the same as an active ingredient, and the existing document [Haidasz, EA et al., Org Lett., 19(7), 1854-1857, 2017] discloses the synthesis of diazaphenoxazine and diazaphenothiazine derivatives. However, in the prior art, there is no report on the MLK3 and LRRK2 inhibitory activities of the pyrimidine derivatives represented by Chemical Formulas 1 and 2 of the present invention and the above-mentioned derivatives, and the treatment of cancer, viral infectious diseases, Parkinson's disease, non-alcoholic fatty liver disease and tuberculosis by using the same. Thus, the present inventors completed the present invention by confirming the MLK3 inhibitory activity and the LRRK2 inhibitory activity during the study of pyrimidine derivatives. Summary of the invention

[0010] Problem that the invention aims to solve

[0011] The purpose of the present invention relates to novel pyrimidine derivatives and uses thereof, and more specifically, to provide a novel pyrimidine derivative having MLK3 inhibitory activity and LRRK2 inhibitory activity and a pharmaceutical composition containing the same for preventing or treating cancer, viral infectious diseases, Parkinson's disease, non-alcoholic fatty hepatitis and tuberculosis.

[0012] Means used to solve problems

[0013] The present invention relates to a compound represented by the following Chemical Formulas 1 to 10 or a pharmaceutically acceptable salt thereof.

[0014] The present invention relates to a compound represented by the following Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof.

[0015] [Chemical formula 1]

[0016]

[0017] In the above chemical formula 1,

[0018] R1 is selected from substituted or unsubstituted C4-C 12 Aryl, substituted or unsubstituted C4-C 12 Heterocycloalkyl, substituted or unsubstituted C4-C 12 Heterobicycloalkyl, substituted or unsubstituted C4-C 12 Cycloalkyl, substituted or unsubstituted C4-C12 One or more substituents from the group consisting of heterocyclic aromatic groups;

[0019] Wherein, the above-mentioned substituted aryl, heterocycloalkyl, heterobicycloalkyl, cycloalkyl or heteroaryl is selected from hydrogen, Substituted with more than one substituent in the group consisting of;

[0020] X is one or more substituents selected from the group consisting of hydrogen, halogen, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy;

[0021] R2 is one or more substituents selected from the group consisting of hydrogen, C1-C4 alkyl or acetyl;

[0022] R3 is selected from substituted or unsubstituted C4-C 12 Aryl, substituted or unsubstituted C4-C 12 Heterobicycloalkyl, substituted or unsubstituted C4-C 12 One or more substituents in the group consisting of heterobicyclic aromatic groups,

[0023] The substituted aryl, heterobicycloalkyl, and heterobicycloaryl are selected from hydrogen, halogen, cyano, aldehyde, CF3, SH, trifluoroketone, C1-C6 alkyl, C1-C6 alkoxy, substituted or unsubstituted C4-C 12 Cycloalkyl, substituted or unsubstituted C4-C 12 Heterocycloalkyl, substituted or unsubstituted C4-C 12 Aryl, or substituted or unsubstituted C4-C 12 is substituted with one or more substituents from the group consisting of heteroaryl,

[0024] Furthermore, the above-mentioned substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted by one or more substituents selected from the group consisting of hydrogen, halogen, NH2, hydroxyl, CF3, NO2, methanesulfonate, Boc (tert-butyloxycarbonyl), ketone, aldehyde, C1-C6 hydroxyalkyl, C1-C6 alkoxy, piperazine or C1-C6 alkyl.

[0025] The present invention relates to a compound represented by the following Chemical Formula 2 to Chemical Formula 9, an optical isomer thereof, or a pharmaceutically acceptable salt thereof.

[0026] [Chemical formula 2]

[0027]

[0028] [Chemical formula 3]

[0029]

[0030] [Chemical formula 4]

[0031]

[0032] [Chemical formula 5]

[0033]

[0034] [Chemical formula 6]

[0035]

[0036] [Chemical formula 7]

[0037]

[0038] [Chemical formula 8]

[0039]

[0040] [Chemical formula 9]

[0041]

[0042] In the above chemical formula,

[0043] R1 is substituted or unsubstituted C4-C 12 Aryl;

[0044] Wherein, the above-mentioned substituted aryl is selected from hydrogen, Substituted with more than one substituent in the group consisting of;

[0045] X is one or more substituents selected from the group consisting of hydrogen, halogen, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy;

[0046] R2 is one or more substituents selected from the group consisting of hydrogen, C1-C4 alkyl or acetyl;

[0047] R4 is selected from hydrogen, halogen, cyano, aldehyde, CF3, SH, trifluoroketone, C1-C6 alkyl, C1-C6 alkoxy, substituted or unsubstituted C4-C 12 Cycloalkyl, substituted or unsubstituted C4-C 12 Heterocycloalkyl, substituted or unsubstituted C4-C 12 Aryl, or substituted or unsubstituted C4-C 12 One or more substituents in the group consisting of heteroaryl,

[0048] The substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted by one or more substituents selected from the group consisting of hydrogen, halogen, NH2, hydroxyl, CF3, NO2, methanesulfonate, Boc (tert-butyloxycarbonyl), ketone, aldehyde, C1-C6 hydroxyalkyl, C1-C6 alkoxy, piperazine or C1-C6 alkyl;

[0049] R5 is selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, thio C1-C4 alkyl, and amino.

[0050] Also, the present invention relates to a compound represented by the following Chemical Formula 10, an optical isomer thereof, or a pharmaceutically acceptable salt thereof.

[0051] [Chemical formula 10]

[0052]

[0053] In the above chemical formula 10,

[0054] R1 is substituted or unsubstituted C4-C 12 Aryl;

[0055] Wherein, the above-mentioned substituted aryl is selected from hydrogen, Substituted with more than one substituent in the group consisting of;

[0056] X is one or more substituents selected from the group consisting of hydrogen, halogen, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy;

[0057] R2 is one or more substituents selected from the group consisting of hydrogen, C1-C4 alkyl or acetyl;

[0058] R6 is one or more substituents selected from the group consisting of hydrogen, C1-C6 alkyl, halogenated C1-C6 alkylcarbonyl, trifluoromethylcarbonyl, acetyl, and Boc (tert-butyloxycarbonyl);

[0059] R7 is one or more substituents selected from the group consisting of hydrogen, C1-C6 alkyl, halogen, and hydroxyl;

[0060] n is an integer of 0 or 1;

[0061] m is an integer of 0, 1 or 2.

[0062] Unless otherwise specified, the following terms in the present invention have the following meanings. Any undefined terms have the meanings commonly understood in the art.

[0063] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0064] The term "alkyl" refers to a straight or branched hydrocarbon group with a single bond, for example, methyl, ethyl, propyl, n-butyl, isobutyl, tert-butyl, 1-methylpropyl, etc.

[0065] The term "alkoxy" refers to an oxy group of a straight or branched saturated hydrocarbon bonded with a single bond, for example, methoxy, ethoxy, propoxy, n-butoxy, tert-butoxy, 1-methylpropoxy, and the like.

[0066] The term "cycloalkyl" refers to a cyclic single-bonded saturated hydrocarbon group, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.

[0067] The above-mentioned terms "heterocycloalkyl", "heterobicycloalkyl", "heterobicycloaryl" or "heteroaryl" refer to a cyclic saturated hydrocarbon group containing one or more hetero atoms such as N, O or S, and include indazole, indole, tetrahydroisoquinoline, quinoline, isoquinoline, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolyl, furanyl, pyridinyl, pyrimidinyl, pyran and the like, depending on the number and type of hetero atoms contained in the ring and the number of carbon atoms.

[0068] The term "aryl" refers to an aromatic substitution product having at least one ring having a conjugated π electron system, for example, phenyl, benzyl, and the like.

[0069] In addition, the compounds of the present invention may contain more than one asymmetric carbon atom and may exist in racemic and optically active forms. All these compounds and diastereomers are included within the scope of the present invention.

[0070] In the present invention, the pharmaceutically acceptable salts refer to salts or complexes of chemical formulas 1 to 10 having preferred biological activity. Examples of these salts include, but are not limited to, acid addition salts formed from inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.); and salts formed from organic acids (e.g., acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalene disulfonic acid, and polygalacturonic acid). The above compounds can also be administered in the form of pharmaceutically acceptable quaternary salts known to those skilled in the art, in particular, chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methanesulfonate, sulfonate, phosphate or carboxylate (e.g., benzoate, succinate, acetate, glycolate, maleate, malate, fumarate, citrate, tartrate, ascorbate, cinnamate, mandelate and diphenylacetate). The compounds of Chemical Formulas 1 to 10 of the present invention include not only pharmaceutically acceptable salts, but also all salts, hydrates, solvates and prodrugs that can be prepared by conventional methods.

[0071] The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the derivatives of Chemical Formulas 1 to 10 in an organic solvent (e.g., methanol, ethanol, acetone, dichloromethane, acetonitrile, etc.), adding an organic acid or an inorganic acid, filtering the resulting precipitate and drying it, or, distilling the solvent and excess acid under reduced pressure, drying it, and crystallizing it under organic solvent conditions.

[0072] In addition, pharmaceutically acceptable salts can be prepared by using a base. For example, the compound is dissolved in an excess of an alkali metal hydroxide or alkaline earth metal hydroxide solution, the undissolved compound salt is filtered, and the filtrate is evaporated and dried to obtain an alkali metal salt or an alkaline earth metal salt. In this case, as a metal salt, a sodium salt, a potassium salt or a calcium salt is prepared for pharmaceutical use. In addition, the corresponding salt is obtained by reacting an alkali metal salt or an alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).

[0073] On the other hand, the present invention relates to a pharmaceutical composition for preventing or treating cancer, Parkinson's disease, viral infectious diseases and tuberculosis, comprising the compounds represented by the above Chemical Formulas 1 to 10 as active ingredients, wherein the compounds represented by the above Chemical Formulas 1 to 10 have the activity of inhibiting both MLK3 and LRRK2.

[0074] Furthermore, the above-mentioned cancer can be selected from the group consisting of lung cancer, liver cancer, stomach cancer, colorectal cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, thyroid cancer, melanoma, blood cancer, colon cancer, non-small cell lung cancer, pancreatic cancer, skin cancer, head and neck cancer, small intestine cancer, rectal cancer, endometrial cancer, vaginal cancer, testicular cancer, esophageal cancer, bile duct cancer, lymph node cancer, gallbladder cancer, endocrine gland cancer, adrenal cancer, lymphoma, multiple myeloma, thymoma, mesothelioma, kidney cancer, brain cancer, central nervous system tumors, brain stem glioma and pituitary adenoma, but is not particularly limited thereto.

[0075] The viral infectious disease may be a disease caused by one or more viruses selected from the group consisting of Zika virus, human immunodeficiency virus (HIV), influenza virus, influenza A virus subtype H1N1, avian influenza virus, rhinovirus, adenovirus, coronavirus, parainfluenza virus, respiratory syncytial virus, herpes virus (HSV), rotavirus and hepatitis virus, but is not particularly limited thereto.

[0076] The pharmaceutical composition according to the present invention can be formulated into a suitable form together with a commonly used pharmaceutically acceptable carrier. "Pharmaceutically acceptable salt" refers to a physiologically acceptable composition, and when administered to humans, it usually does not cause allergic reactions (such as gastrointestinal disorders, dizziness) or similar reactions. In addition, the above-mentioned composition can be formulated into oral dosage forms (such as powders, granules, tablets, capsules, emulsions, syrups, sprays), external preparations, suppositories and sterile injection solutions for use according to conventional methods.

[0077] The carrier, excipient and diluent that can be included in the above-mentioned composition can include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone (Polyvinylpyrrolidone), water, methyl paraoxybenzoate (methyl paraoxybenzoate), propylparaoxybenzoate (propylparaoxybenzoate), talc, magnesium stearate and mineral oil, but are not limited to this. In the case of preparation, diluent or excipient preparation is used, such as commonly used fillers, stabilizers, adhesives, disintegrants, surfactants, etc. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., which are prepared by mixing at least one or more excipients (for example, starch, microcrystalline cellulose, sucrose or lactose, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose) in the compound of the present invention. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid phase preparations for oral administration include suspensions, oral solutions, emulsions, syrups, etc., and in addition to water and liquid paraffin as commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, preservatives, etc. are also included. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils (such as olive oil) and injectable esters (such as ethyl oleate) can be used as non-aqueous solvents and suspension solvents. As the base of suppositories, semi-synthetic fatty acid esters (witepsol), polyethylene glycol (Macrogol), Tween (tween) 61, cocoa butter, laurin, glycerol, gelatin, etc. can be used. In order to formulate into dosage forms for parenteral administration, the pyrimidine derivative compounds of the above chemical formulas 1 to 10 or their pharmaceutically acceptable salts are sterilized, or mixed in water with auxiliary agents (such as preservatives, stabilizers, hydrating agents or emulsifying agents, salts or buffers for osmotic pressure regulation, etc.) and other therapeutically useful substances to prepare, and they can be prepared into ampoule or vial unit dosage forms.

[0078] The pharmaceutical composition comprising the compounds of Chemical Formulae 1 to 10 disclosed in the present invention as an effective ingredient can be administered to mammals such as mice, livestock and humans through various routes.

[0079] Any mode of administration can be envisioned, for example, administration can be carried out by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura mater or intracerebral injection. The dosage can be different according to the age, sex, weight, specific disease or pathological state treated, severity of the disease or pathology, administration time, route of administration, absorption, distribution and excretion rate of the drug, the type of other drugs used and the judgment of the prescribing personnel, etc. of the subject being treated. The dosage based on these factors is determined within the capabilities of those skilled in the art, and the dosage range is generally from 0.01 mg / kg / day to about 2000 mg / kg / day. A more preferred dosage is from 1 mg / kg / day to 500 mg / kg / day. Administration can be once a day, or it can be divided into several doses. The above dosage does not limit the scope of the present invention in any way.

[0080] Furthermore, in order to prevent or treat cancer, viral infectious diseases, Parkinson's disease, non-alcoholic fatty hepatitis and tuberculosis, the above-mentioned pharmaceutical composition of the present invention can be used alone, or can also be used in combination with surgery, hormone therapy, chemotherapy and the use of biological response modifiers.

[0081] Effects of the Invention

[0082] The present invention relates to novel pyrimidine derivatives and uses thereof. The pyrimidine derivatives have excellent MLK3 inhibitory activity and LRRK2 inhibitory activity, and thus can be effectively used as pharmaceutical compositions for preventing or treating cancer, viral infectious diseases, Parkinson's disease, nonalcoholic steatohepatitis and tuberculosis. DETAILED DESCRIPTION

[0083] The preferred embodiments of the present invention are described in detail below. However, the present invention is not limited to the embodiments described here and can be embodied in other forms, but is provided to make the contents introduced here thorough and complete and to fully convey the spirit of the present invention to those skilled in the art.

[0084] Example 1. Synthesis of pyrimidine derivatives and confirmation of their physicochemical properties

[0085] The synthesis processes and physicochemical properties of compounds 1 to 119 of the present invention are as follows.

[0086] Compound 1: 5-Chloro-N 2 -(3,5-dimethoxyphenyl)-N 4 -(2-(Isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (5-Chloro-N 2 -(3,5-dimethoxyphenyl)-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine)

[0087] [Reaction 1]

[0088]

[0089] 2,5-Dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]pyrimidin-4-amine (30 mg, 0.087 mmol) was added to 0.08 M HCl (1 ml) mixed with ethoxyethanol, and the mixture was heated overnight at 80° C. to which 3,5-dimethoxyaniline (15 mg, 0.095 mmol) was added. The reaction was terminated by adding water, and then extracted with dichloromethane (DCM) (2×25 ml). Thereafter, the organic layer was dried by adding Na2SO4, and after removing the solvent under vacuum conditions, the crude mixture was purified by preparative thin layer chromatography using EA:MC (1 / 4) as eluent to obtain the compound 1 of the present invention (15 mg, 0.032 mmol, 38%, ivory solid).

[0090] 1H NMR (300MHz, CDCl3) δ9.64 (s, 1H), 8.63 (dd, J1=9.0Hz, J2=0.0Hz, 1H), 8.18 (s, 1H), 7.93 (dd, J1=7.5Hz, J2=3.0Hz, 1H), 7.66 (t, J=7.5Hz, 1 H), 7.30 (t, J=15Hz, 1H), 6.96 (s, 1H), 6.72 (d, J=6.0Hz, 1H), 6.24-6.20 (m, 1H), 3.77 (s, 6H), 3.32-3.19 (m, 1H), 1.34 (s, 3H), 1.32 (s, 3H).

[0091] LC / MS (ESI) m / z 463.5 [M+H]+.

[0092] Compound 2: 5-Chloro-N 2 -(3,5-dichlorophenyl)-N 4 -(2-(Isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (5-Chloro-N 2-(3,5-dichlorophenyl)-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine)

[0093] [Reaction 2]

[0094]

[0095] 3,5-Dichloroaniline (15 mg, 0.095 mmol) was dissolved in 0.08 M HCl (1 ml) mixed with ethoxyethanol, and pyrimidineamine, 2,5-dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]pyrimidine-4-amine (30 mg, 0.087 mmol) were added, and heated at 80°C overnight. The reaction was terminated by adding water to the above reactants, and then extracted with dichloromethane (DCM) (2×25 ml). Thereafter, the organic layer was dried by adding Na2SO4, and after removing the solvent under vacuum, the above crude reaction (crude mixture) was purified by preparative thin layer chromatography using ethyl acetate / dichloromethane (EA:MC) (1 / 4) as an eluent to obtain the present compound 2 (14 mg, 0.030 mmol, 34%, light pink solid).

[0096] 1H NMR (300MHz, CDCl3) δ9.65 (s, 1H), 8.47 (dd, J1=9.0Hz, J2=0.0Hz, 1H), 8.20 (s, 1H), 7.96 (dd, J1=9.0Hz, J2=0.0Hz, 1H), 7.76 (t, J= 15Hz, 1H), 7.51 (d, J=1.8Hz, 1H), 7.32 (t, J=18Hz, 1H), 7.06 (s, 1H), 7.05-7.00 (m, 1H), 3.32-3.20 (m, 1H), 1.35 (s, 3H), 1.32 (s, 3H).

[0097] LC / MS (ESI) m / z 471.3 [M+H]+.

[0098] Compound 3: 5-Chloro-N 2 -(3,5-dimethylphenyl)-N 4 -(2-(Isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (5-Chloro-N 2 -(3,5-dimethylphenyl)-N4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine)

[0099] [Reaction 3]

[0100]

[0101] Pyrimidineamine and 2,5-dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]pyrimidine-4-amine (30 mg, 0.087 mmol) were added to 0.08 M HCl (1 ml) mixed with ethoxyethanol, and the mixture to which 3,5-dimethylaniline (0.022 ml, 0.17 mmol) was added was heated overnight at 80°C. The reaction was terminated by adding water to the above reactants, and then extracted with dichloromethane (DCM) (2×25 ml). Thereafter, the organic layer was dried by adding Na2SO4, and after removing the solvent under vacuum, the above crude reaction (crude mixture) was purified by preparative thin layer chromatography (preparative thin layer chromatography) using EA:MC (1 / 4) as an eluent to obtain the present compound 3 (17 mg, 0.039 mmol, 45%, beige solid).

[0102] 1H NMR (300MHz, CDCl3) δ10.69 (s, 1H), 10.58 (s, 1H), 8.45 (dd, J1=9.0Hz, J2=0.9Hz, 1H), 8.00 (dd, J1=9.0Hz, J2=9.3Hz, 1H), 7.95 (s, 1H) , 7.61 (t, J=15Hz, 1H), 7.46 (t, J=15Hz, 1H), 7.17-7.13 (m, 2H), 6.90 (s, 1H), 3.30-3.17 (m, 1H), 2.29 (s, 6H), 1.36 (s, 3H), 1.34 (s, 3H).

[0103] LC / MS (ESI) m / z 346.3 [M+H]+.

[0104] Compound 4: N 2 -(4-bromo-3,5-difluorophenyl)-5-chloro-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (N 2 -(4-Bromo-3,5-difluorophenyl)-5-chloro-N4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine)

[0105] [Reaction 4]

[0106]

[0107] 4-Bromo-3,5-difluoroaniline (40 mg, 0.19 mmol) was dissolved in 0.08 M HCl (1 ml) mixed with ethoxyethanol, and pyrimidineamine, 2,5-dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]pyrimidine-4-amine (30 mg, 0.087 mmol) were added, and heated at 80°C overnight. The above reactants were cooled to room temperature and the solid precipitate was filtered. The above solid filtrate was washed with ethanol (EtOH) and dried to obtain compound 4 of the present invention (15 mg, 0.029 mmol, 33%, beige solid).

[0108] 1H NMR (300MHz, DMSO-d6) δ10.09 (s, 1H), 9.44 (s, 1H), 8.40 (s, 1H), 8.39-8.33 (m, 1H), 7.90 (dd, J1=14Hz , J2=8.4Hz, 1H), 7.82 (t, J=15Hz, 1H), 7.58-7.45 (m, 3H), 3.53-3.41 (m, 1H), 1.16 (s, 3H), 1.14 (s, 3H).

[0109] LC / MS (ESI) m / z 516.8 [M+H]+.

[0110] Compound 5: N 2 -(3,5-bis(trifluoromethyl)phenyl)-5-chloro-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (N2-(3,5-Bis(trifluoromethyl)phenyl)-5-chloro-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine)

[0111] [Reaction 5]

[0112]

[0113] 3,5-bis(trifluoromethyl)aniline (0.030 ml, 0.19 mmol) was dissolved in 0.08 M HCl (1 ml) mixed with ethoxyethanol, and pyrimidineamine and 2,5-dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]pyrimidine-4-amine (30 mg, 0.087 mmol) were added, and heated at 80°C overnight. The reaction was terminated by adding water to the above reactants, and then extracted with dichloromethane (DCM) (2×25 ml). Thereafter, the organic layer was dried by adding Na2SO4, and after removing the solvent under vacuum, the above crude reaction (crude mixture) was purified by preparative thin layer chromatography (preparative thin layer chromatography) using 100% dichloromethane (MC) as an eluent to obtain the present compound 5 (25 mg, 0.046 mmol, 53%, white solid).

[0114] 1H NMR (300MHz, CDCl3) δ9.63 (s, 1H), 8.36 (d, J=8.4Hz, 1H), 8.252 (s, 1H), 8.05 (m, 2H), 7.97 (dd, J1=9.0Hz, J2=1.8Hz, 1H ), 7.64 (t, J=15Hz, 1H), 7.512 (s, 1H), 7.33 (t, J=16Hz, 1H), 7.246 (s, 1H), 3.32-3.21 (m, 1H), 1.34 (s, 3H), 1.32 (s, 3H).

[0115] LC / MS (ESI) m / z 538.9 [M+H]+.

[0116] Compound 6: 5-Chloro-N 2 -(3,5-difluorophenyl)-N 4 -(2-(Isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (5-Chloro-N 2 -(3,5-difluorophenyl)-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine)

[0117] [Reaction 6]

[0118]

[0119] 3,5-difluoroaniline (25 mg, 0.19 mmol) was dissolved in 0.08 M HCl (1 ml) mixed with ethoxyethanol, and pyrimidineamine and 2,5-dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]pyrimidine-4-amine (30 mg, 0.087 mmol) were added, and heated at 80°C overnight. The above reaction was cooled to room temperature and the solid precipitate was filtered. The above solid filtrate was washed with EtOH and dried to obtain compound 6 of the present invention (32 mg, 0.073 mmol, 84%, light pink solid).

[0120] 1H NMR (300MHz, CDCl3) δ9.64 (s, 1H), 8.49 (dd, J1=9.0Hz, J2=0.9Hz, 1H), 8.209 (s, 1H), 7.95 (dd, J1=9.0Hz, J2=1.5Hz, 1H), 7.73 (t, J= 15Hz, 1H), 7.33 (t, J=18Hz, 1H), 7.24-7.13 (m, 1H), 7.09 (s, 1H), 6.50 (t, J=14Hz, 1H), 3.31-3.20 (m, 1H), 1.35 (s, 3H), 1.32 (s, 3H).

[0121] LC / MS (ESI) m / z 438.9 [M+H]+.

[0122] Compound 7: (2-((5-Chloro-2-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide)

[0123] [Reaction 7]

[0124]

[0125] To a solution of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-amine (39 mg, 0.19 mmol) in isopropanol (IPA) (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol) and then p-toluenesulfonamide (PTSA) (30 mg, 0.16 mmol). The reaction mixture was heated at 80°C overnight. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain compound 7 (43 mg, 0.089 mmol, 56%) as a beige solid.

[0126] LC / MS (ESI) m / z 483.7 [M+H]+.

[0127] 1H NMR (300MHz, CDCl3) δ10.90 (s, 1H), 8.64 (dd, J=9.0, 3.0Hz, 1H), 8.11 (s, 1H), 7.58 (dd, J=9.0, 3.0Hz, 1H), 7.46 (t, J =9.0Hz, 1H), 7.33-7.26(m, 2H), 7.20-7.09(m, 2H), 1.87(s, 3H), 1.83(s, 3H), 1.70(s, 4H), 1.30(s, 6H), 1.26(s, 6H).

[0128] Compound 8: (2-((5-Chloro-2-(quinolin-5-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0129] [Reaction formula 8]

[0130]

[0131] To a solution of 1H-indol-5-amine (25 mg, 0.19 mmol) in IPA (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol), followed by PTSA (30 mg, 0.16 mmol). The reaction mixture was heated overnight at 80°C. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain compound 8 (9.5 mg, 0.022 mmol, 14%) as a solid.

[0132] LC / MS (ESI) m / z 424.5 [M+H]+.

[0133] 1H NMR (300MHz, CDCl3) δ11.12 (s, 1H), 8.96 (dd, J=6.0, 4.0Hz, 1H), 8.47-8.38 (m, 1H), 8.15-8.06 (m, 2H), 8.04 (d, J=9.0Hz, 1H), 7.89-7.8 3 (m, 1H), 7.79-7.71 (m, 1H), 7.51 (bs, 1H), 7.43 (dd, J=9.0, 3.0Hz, 1H), 7.24-7.14 (m, 1H), 7.07-6.95 (m, 2H), 1.84 (s, 3H), 1.79 (s, 3H).

[0134] Compound 9: (2-((2-(5-Amino-3,4-dihydroisoquinolin-2(1H)-yl)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0135] [Reaction formula 9]

[0136]

[0137] 2,5-Dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol) was added to a solution of 1,2,3,4-tetrahydroisoquinolin-5-amine (28 mg, 0.19 mmol) in IPA (0.6 ml), and then PTSA (30 mg, 0.16 mmol) was added. The reaction mixture was heated at 80°C overnight. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain compound 9 (14 mg, 0.033 mmol, 21%) as a solid.

[0138] LC / MS (ESI) m / z 428.6 [M+H]+.

[0139] 1H NMR (300MHz, CDCl3) δ10.79 (s, 1H), 8.77-8.62 (m, 1H), 8.08 (s, 1H), 7.57 ( t, J=6.0Hz, 1H), 7.35-7.26 (m, 1H), 7.17-7.09 (m, 1H), 7.05 (t, J=9.0Hz, 1H ), 6.67 (d, J=9.0Hz, 1H), 6.60 (d, J=6.0Hz, 1H), 4.88 (s, 2H), 4.11 (t, J=6. 0Hz, 2H), 3.78-3.52 (m, 2H), 2.68 (t, J=6Hz, 2H), 1.88 (s, 3H), 1.83 (s, 3H).

[0140] Compound 10: (2-((5-Chloro-2-((2-methylpyridin-4-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0141] [Reaction formula 10]

[0142]

[0143] To a solution of 2-Methylpyridin-4-amine (26 mg, 0.24 mmol) in N,N-dimethylformamide (DMF) (0.5 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (46 mg, 0.24 mmol). The reaction mixture was heated at 120 ° C for 30 minutes in a microwave reactor. The reaction mixture was poured into H2O and extracted with ethyl acetate (EA) (2×25 ml). The combined organic layers were dried over Na2SO4 and the solvent was removed under vacuum. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain compound 10.

[0144] LC / MS (ESI) m / z 325.4 [M+H]+.

[0145] 1H NMR (300MHz, CDCl3) δ10.81 (s, 1H), 8.82-8.75 (m, 1H), 8.05 (s, 1H), 7.54-7 .46 (m, 1H), 7.33-7.24 (m, 1H), 7.13-7.05 (m, 1H), 1.87 (s, 3H), 1.83 (s, 3H).

[0146] Compound 11: (2-((2-(Benzo[d]thiazol-6-ylamino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0147] [Reaction formula 11]

[0148]

[0149] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) was added to a solution of 6-aminobenzothiazole (36 mg, 0.24 mmol) dissolved in DMF (0.5 ml). Then, PTSA (46 mg, 0.24 mmol) was added. The reaction mixture was heated at 180 ° C for 30 minutes in a microwave reactor. The reaction mixture was poured into H2O and extracted with ethyl acetate (EA) (2×25 ml). The combined organic layers were dried over Na2SO4 and the solvent was removed under vacuum. The unpurified mixture was purified by silica gel column chromatography using MC:MeOH (9.5 / 0.5) to obtain compound 11 (26 mg, 0.060 mmol, 38%) as a yellow solid.

[0150] LC / MS (ESI) m / z 430.4 [M+H]+.

[0151] 1H NMR (300MHz, CDCl3) δ10.97 (s, 1H), 8.89 (s, 1H), 8.62-8.54 (m, 2H), 8.17 (s, 1H), 8.05 (d, J=8.7Hz, 1H), 7.5 7-7.49 (m, 1H), 7.41 (dd, J=8.7, 2.1Hz, 1H), 7.38-7.29 (m, 2H), 7.23-7.15 (m, 1H), 1.90 (s, 3H), 1.85 (s, 3H).

[0152] Compound 12: (2-((5-Chloro-2-((4-fluorobenzyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0153] [Reaction 12]

[0154]

[0155] To a solution of (4-fluorophenyl)methaNamine (0.28 ml, 0.19 mmol) dissolved in dimethyl sulfoxide (DMSO) (0.5 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), and then PTSA (9.1 mg, 0.048 mmol) was added. The reaction mixture was heated at 120 ° C for 30 minutes in a microwave reactor. The reaction was quenched with water and extracted with EtOAc (2×25 ml). The combined organic layers were dried over MgSO4 and the solvent was removed under vacuum. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain solid compound 12.

[0156] LC / MS (ESI) m / z 405.4[M+H]+, 407.4[M+H]+.

[0157] 1H NMR (300 MHz, CHLOROFORM-d) δ 10.87 (s, 1H), 8.55-8.42 (m, 1H), 8.03 (s, 1H), 7.41-7.30 (m, 3H), 7.28-7.21 (m, 1H), 7.11-6.98 (m, 3H), 5.39-5.33 (m, 1H), 4.58 (d, J=6.0 Hz, 2H), 1.86 (s, 3H), 1.82 (s, 3H).

[0158] Compound 13: (2-((5-Chloro-2-(cyclopentylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide

[0159] [Reaction 13]

[0160]

[0161] To a solution of cyclopentylamine (0.019 ml, 0.19 mmol) dissolved in DMSO (0.5 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (9.1 mg, 0.048 mmol). The reaction mixture was heated at 130 ° C for 30 minutes in a microwave reactor. The reaction was quenched with water and extracted with EtOAc (2×25 ml). The combined organic layers were dried over Na2SO4 and the solvent was removed under vacuum. The crude mixture was purified by silica gel column chromatography using DCM:MeOH (9.5 / 0.5) to obtain compound 13 (45 mg, 0.12 mmol, 78%) as a beige solid.

[0162] LC / MS(ESI)m / z[M+H]+, [M+H]+.

[0163] 1H NMR (300 MHz, CHLOROFORM-d) δ 10.83 (s, 1H), 8.86-8.58 (m, 1H), 8.00 (s, 1H), 7.51 (td, J=8.7, 7.2 Hz, 1H), 7.33-7.22 (m, 1H), 7.10 (tdd, J=7.4, 2.4, 1.1 Hz, 1H), 4.94 (d, J=7.1 Hz, 1H), 4.22 (h, J=6.5 Hz, 1H), 2.13-1.98 (m, 2H), 1.80-1.59 (m, 4H), 1.58-1.45 (m, 2H).

[0164] Compound 14: (2-((2-(Benzylamino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide

[0165] [Reaction 14]

[0166]

[0167] To a solution of benzylamine (0.021 ml, 0.19 mmol) dissolved in DMSO (0.4 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (9.1 mg, 0.048 mmol). The reaction mixture was heated at 130 ° C for 30 minutes in a microwave reactor. The reaction was quenched with water and extracted with EtOAc (2×25 ml). The combined organic layers were dried over Na2SO4 and the solvent was removed under vacuum. The crude mixture was purified by silica gel column chromatography using DCM:MeOH (9.5 / 0.5) to obtain compound 14 (27 mg, 0.070 mmol, 44%) as an ivory solid.

[0168] LC / MS(ESI)m / z[M+H]+, [M+H]+.

[0169] 1H NMR (300 MHz, CHLOROFORM-d) δ 10.85 (s, 1H), 8.47 (s, 1H), 8.02 (s, 1H), 7.37 (d, J = 4.4 Hz, 4H), 7.36-7.18 (m, 3H), 7.07 (tdd, 1H), 5.40 (s, 1H), 4.62 (d, J = 5.9 Hz, 2H), 1.86 (s, 3H), 1.81 (s, 3H).

[0170] Compound 15: (2-((5-Chloro-2-(pyridin-4-ylamino)pyrimidin-4-ylamino)phenyl)dimethylphosphine oxide

[0171] [Reaction 15]

[0172]

[0173] To a solution of 4-aminopyridine (18 mg, 0.19 mmol) dissolved in DMSO (0.3 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (9.1 mg, 0.048 mmol). The reaction mixture was heated at 130 ° C for 30 minutes in a microwave reactor. The reaction was quenched with water and extracted with EtOAc (2×25 ml). The combined organic layers were dried over Na2SO4 and the solvent was removed under vacuum. The crude mixture was purified by silica gel column chromatography using DCM:MeOH (9.5 / 0.5) to obtain compound 15 (4.7 mg, 0.013 mmol, 7.8%) as an ivory solid.

[0174] LC / MS(ESI)m / z[M+H]+, [M+H]+.

[0175] 1H NMR (300MHz, chloroform-d) δ11.57 (s, 1H), 8.69 (dd, J=8.6, 4.4Hz, 1H), 8.25 (s, 1H), 7.62 (t , J=8.0Hz, 1H), 7.28 (s, 4H), 7.21 (dt, J=8.5, 4.2Hz, 1H), 1.89 (s, 3H), 1.85 (s, 3H).

[0176] Compound 16: (2-((5-Chloro-2-(cyclohexylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide

[0177] [Reaction 16]

[0178]

[0179] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (51 mg, 0.16 mmol) in IPA (1 mL) was added cyclohexylamine (0.66 ml, 0.57 mmol), followed by PTSA (30 mg, 0.16 mmol). The reaction mixture was heated overnight at 80 °C. The crude mixture was purified by silica gel column chromatography using EA:Hex (9.5 / 0.5). Compound 16 (46 mg, 0.12 mmol, 76%) was then obtained as a white solid by fine powdering.

[0180] LC / MS (ESI) m / z 379.5 [M+H]+, [MH]-.

[0181] 1H NMR (300MHz, CDCl3) δ11.09 (s, 1H), 8.73 (s, 1H), 7.99 (s, 1H), 7.69-7.47 (m, 2H), 7.16-7.10 (m, 1H), 7.00 (s, 1H), 3.58 (s, 1H), 2.51 (p, J=3. 9, 1.8Hz, 6H), 1.90 (d, J = 7.8Hz, 2H), 1.83 (s, 1H), 1.81 (s, 2H), 1.79 (s, 1H), 1.72 (s, 1H), 1.61 (d, J = 12.6Hz, 1H), 1.28 (s, 1H), 1.24 (s, 1H).

[0182] Compound 17: (2-((5-Chloro-2-((2-methylbenzo[d]thiazol-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0183] [Reaction 17]

[0184]

[0185] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (51 mg, 0.16 mmol) in IPA (1 ml) was added 2-methylbenzo[d]thiazol-6-amine (39 mg, 0.24 mmol), followed by PTSA (46 mg, 0.24 mmol). The reaction mixture was heated at 90°C overnight. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain compound 17 (1.7 mg, 0.0038 mmol, 2.4%) as a yellow solid.

[0186] LC / MS(ESI)m / z[M+H]+,[MH]-.

[0187] 1H NMR (300MHz, CDCl3) δ10.97 (s, 1H), 8.58 (q, J=8.7, 4.5Hz, 1H), 8.43 (d, J=2.1Hz, 1H), 8.14 (s, 1H), 7.86 (d, J=8.7Hz, 1H), 7.56-7.51 (m, J=7.5 Hz, 1H), 7.46 (s, 1H), 7.36 (dd, J=8.7, 2.1Hz, 1H), 7.33-7.30 (m, J=7.8, 1.8Hz, 1H), 7.23-7.18 (m, 1H), 2.85 (s, 3H), 1.90 (s, 3H), 1.85 (s, 3H).

[0188] Compound 18: (2-((5-Chloro-2-(quinolin-6-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0189] [Reaction 18]

[0190]

[0191] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol) to a solution of quinoline-6-amino (28 mg, 0.19 mmol) dissolved in IPA (0.6 ml), PTSA.H2O (36 mg, 0.19 mmol) was added. The reaction mixture was heated overnight at 80°C. Thin layer chromatography (TLC) showed the formation of a new spot. The reaction was quenched with sodium bicarbonate and extracted with DCM (20 ml×2). The organic layer was dried with sodium sulfate and the solvent was distilled under vacuum. The unpurified mixture was purified by medium pressure liquid chromatography (MPLC) using 5% MeOH:DCM as a solvent mixture to obtain compound 18 (51 mg, 0.120 mmol, 75%) as a fluffy solid.

[0192] LCMS: 424.2 [M+H]+.

[0193] 1H NMR (400MHz, chloroform-d) δ11.03 (s, 1H), 8.82 (s, 1H), 8.69-8.62 (m, 1H), 8.29 (s, 1H), 8.20 (s, 1H), 8.04 (dd, J=14.6, 8.7Hz, 2H), 7.73 (d, J=9.1Hz, 1H), 7.49 (t, J=7.9Hz, 1H), 7.44-7.30 (m, 3H), 7.21 (t, J=7.7Hz, 1H), 1.90 (s, 3H), 1.87 (s, 3H).

[0194] Compound 19: (2-((5-Chloro-2-(quinolin-3-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0195] [Reaction 19]

[0196]

[0197] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) to a solution of quinolin-3-amine (28 mg, 0.19 mmol) in IPA (0.6 ml), PTSA (46 mg, 0.19 mmol) was added. The reaction mixture was heated overnight at 80 ° C. TLC showed the formation of new spots, the reaction was quenched with sodium bicarbonate and extracted with DCM (20 ml × 2), the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as a solvent mixture and purified by MPLC to obtain compound 19 (60.0 mg, 0.141 mmol, 88%) as a fluffy solid.

[0198] 1H NMR (400MHz, chloroform-d) δ11.03 (s, 1H), 8.80 (s, 1H), 8.74 (s, 1H), 8.61-8.54 (m, 1H), 8.19 (s, 1H), 8.04 (d, J = 8.4Hz, 1H), 7.68 (d, J = 8.2Hz, 1H) , 7.59 (t, J=7.6Hz, 1H), 7.49 (q, J=9.0, 8.5Hz, 2H), 7.37-7.31 (m, 1H), 7.31-7.28 (m, 1H), 7.19 (t, J=7.7Hz, 1H), 1.88 (s, 3H), 1.85 (s, 3H).

[0199] LCMS: 424.2 [M+H]+.

[0200] Compound 20: (2-((5-Chloro-2-(quinolin-8-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0201] [Reaction 20]

[0202]

[0203] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) to a solution of quinolin-8-amine (28 mg, 0.19 mmol) in IPA (0.6 ml), PTSA (46 mg, 0.19 mmol) was added. The reaction mixture was heated overnight at 80 ° C. TLC showed the formation of new spots, the reaction was quenched with sodium bicarbonate and extracted with DCM (20 ml × 2), the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as a solvent mixture and purified by MPLC to obtain compound 20 (55.0 mg, 0.141 mmol, 88%) as a fluffy solid.

[0204] LCMS 424.6 [M+H]+.

[0205] 1H NMR (400MHz, chloroform-d) δ10.86 (s, 1H), 9.64 (s, 1H), 8.83 (s, 1H), 8.78-8.67 (m, 2H), 8.24 (s, 1H), 8.15 (d, J=8.2Hz, 1H), 7.63 (t, J=8.1Hz, 1H), 7.47 (q, J=11.2, 9.6Hz, 2H), 7.39 (d, J=8.2Hz, 1H), 7.33 (dd, J=14.1, 7.6Hz, 1H), 7.19 (t, J=7.8Hz, 1H), 1.88 (s, 3H), 1.84 (s, 3H).

[0206] Compound 21: (2-((5-Chloro-2-(isoquinolin-5-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0207] [Reaction 21]

[0208]

[0209] 1) Synthesis of isoquinolin-5-amine

[0210] Pd / C (10 mg, 10 mol%) was added to a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (100 mg, 0.413 mmol) in 10 ml of methanol (MeOH), and stirred overnight on a Parr shaker. TLC showed that the reaction was complete, the catalyst was filtered and the solvent was evaporated to obtain compound 20-59 (400 mg, 2.7 mmol, 96%) as a purple solid.

[0211] 1H NMR (500 MHz, CHLOROFORM-d) δ 9.18 (s, 1H), 8.49 (d, J = 6.0 Hz, 1H), 7.58 (d, J = 6.0 Hz, 1H), 7.41 (d, J = 4.6 Hz, 2H), 6.96 (q, J = 4.4 Hz, 1H), 4.22 (s, 2H).

[0212] 2)(2-((5-chloro-2-(isoquinolin-5-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0213] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) to a solution of compound 20-59 (25.0 mg, 0.17 mmol) in IPA (0.6 ml), PTSA (46 mg, 0.19 mmol) was added. The reaction mixture was heated overnight at 80 ° C. TLC showed the formation of new spots, the reaction was quenched with sodium bicarbonate and extracted with DCM (20 ml × 2), the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. For the crude mixture, 5% MeOH:DCM was used as a solvent mixture and purified by MPLC to obtain compound 21 (25 g, 0.050 mmol, 31%) as a fluffy solid.

[0214] LCMS 424.0 [M+H]+.

[0215] 1H NMR (400MHz, chloroform-d) δ10.86 (s, 1H), 9.64 (s, 1H), 8.83 (s, 1H), 8.78-8.67 (m, 2H), 8.24 (s, 1H), 8.15 (d, J=8.2Hz, 1H), 7.63 (t, J=8.1Hz, 1H), 7.47 (q, J=11.2, 9.6Hz, 2H), 7.39 (d, J=8.2Hz, 1H), 7.33 (dd, J=14.1, 7.6Hz, 1H), 7.19 (t, J=7.8Hz, 1H), 1.88 (s, 3H), 1.84 (s, 3H).

[0216] Compound 22: (2-((5-Chloro-2-((2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0217] [Reaction 22]

[0218]

[0219] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50.0 mg, 0.158 mmol) to a 5 mL vial, 2-aminoindane hydrochloride (22.1 mg, 0.166 mmol), PTSA (48.1 mg, 0.506 mmol), and IPA (0.5 ml) were added. The reaction mixture was heated at 100 ° C for 6 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (50 ml × 2) and water, the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. The mixture was purified by MPLC using 4% to 5% MeOH in MC (gradient) to obtain compound 22 (8 mg, 0.0194 mmol, 12%) as a light pink solid.

[0220] 1H NMR (300MHz, CDCl3) δ10.95 (s, 1H), 10.58 (s, 1H), 8.73 (dd, J=8.6, 4.5Hz, 1H), 8.56 (dd, J=8.6, 4.6Hz, 1H), 8.12 (d, J=2.3Hz, 1H), 7.62-7.53 (m, 1H), 7.46 (td, J=7.9, 7.1, 1.4Hz, 1H), 7.27-7.17(m, 4H), 7.16-7.09(m, 1H), 7.09-6.99(m, 1H), 3.99-3.83(m, 1H), 3.24(dd , J=15.8, 6.8Hz, 2H), 2.80 (dd, J=15.8, 5.2Hz, 2H), 1.87-1.85 (m, 3H), 1.84-1.82 (m, 3H).

[0221] Compound 23: (2-((5-Chloro-2-((2-mercaptobenzo[d]thiazol-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0222] [Reaction 23]

[0223]

[0224] To a solution of 6-aminobenzo[d]thiazole-2-thiol (31 mg, 0.17 mmol) in IPA (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by PTSA (46 mg, 0.19 mmol). The reaction mixture was heated overnight at 80°C. TLC showed the formation of new spots, the reaction was quenched with sodium bicarbonate and extracted with DCM (20 ml×2), the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as the solvent mixture and purified by MPLC to obtain flocculent compound 23 (21 mg, 0.045 mmol, 28%).

[0225] LCMS: 462.1 [M+H]+.

[0226] 1H NMR (400MHz, DMSO-d6) δ13.64(s, 1H), 11.06(s, 1H), 9.66(s, 1H), 8.45(s, 1H), 8.22(s, 1H), 8.12(s, 1H), 7.64(d d, J=13.7, 7.7Hz, 1H), 7.54 (t, J=8.0Hz, 1H), 7.46 (d, J=8.8Hz, 1H), 7.36-7.13 (m, 2H), 1.80 (s, 3H), 1.76 (s, 3H).

[0227] Compound 24: (2-((5-Chloro-2-isopropoxypyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0228] [Reaction 24]

[0229]

[0230] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (100 mg, 0.316 mmol) to a 5 mL vial, pyridine p-toluenesulfonate (PPTS) (37.9 mg, 0.285 mmol) was added.

[0231] , PTSA (96.3 mg, 0.506 mmol), IPA (1 ml). The reaction mixture was heated at 100 ° C for 6 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (30 ml × 2) and water. The organic layer was dried over sodium sulfate and the solvent was distilled under vacuum. The mixture was purified by MPLC using 5% MeOH in MC to obtain compound 24 (22 mg, 0.0533 mmol, 17%, white solid).

[0232] 1H NMR (400MHz, CDCl3) δ11.04 (s, 1H), 8.66 (d, J = 9.1Hz, 1H), 8.15 (d, J = 2.3Hz, 1H), 7.54 (t, J = 8.1Hz, 1H), 7.29 (d, J=6.5Hz, 1H), 7.12 (t, J=7.8Hz, 1H), 5.27-5.10 (m, 1H), 1.83 (s, 3H), 1.81 (s, 3H), 1.39 (q, J=2.5Hz, 6H).

[0233] Compound 25: (2-((5-Chloro-2-((6-ethoxybenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0234] [Reaction 25]

[0235]

[0236] 2-Amino-6-ethoxybenzothiazole (37 mg, 0.19 mmol) was dissolved in dioxane (0.6 ml) and then 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol) was added, followed by Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (2.8 mg, 0.0048 mmol) and cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160° C. for 40 minutes using a microwave. The reaction mass was filtered through celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as solvent mixture to obtain Compound 25 (42.0 mg, 0.103 mmol, 55%) as a yellow solid.

[0237] LCMS: 474.2 [M+H]+.

[0238] 1H NMR (400MHz, DMSO-d6) δ11.72 (s, 1H), 11.49 (s, 1H), 8.89 (s, 1H), 8.37 (s, 1H), 7.70-7.55 (m, 2H), 7.55 (d, J=8.8Hz, 1H), 7.44 (d, J= 2.5Hz, 1H), 7.25 (t, J=7.6Hz, 1H), 6.98 (dd, J=8.8, 2.6Hz, 1H), 4.06 (q, J=6.9Hz, 2H), 1.80 (d, J=13.6Hz, 6H), 1.35 (t, J=7.0Hz, 3H).

[0239] Compound 26: (2-((5-Chloro-2-((4-methoxybenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0240] [Reaction 26]

[0241]

[0242] To a solution of 4-methoxybenzo[d]thiazole-2-amine (34 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (2.8 mg, 0.0048 mmol), and cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 ° C for 40 minutes using microwaves. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain yellow solid compound 26 (45.0 mg, 0.097 mmol, 61%).

[0243] 1H NMR (300 MHz, CHLOROFORM-d) δ 11.08 (s, 1H), 8.75 (s, 1H), 8.57 (dd, J=8.5, 4.4 Hz, 1H), 8.28 (s, 1H), 7.59-7.50 (m, 1H), 7.38-7.27 (m, 2H), 7.24-7.15 (m, 2H), 6.87 (dd, J=8.1, 1.0 Hz, 1H), 4.02 (s, 3H), 1.88 (s, 3H), 1.83 (s, 3H).

[0244] Compound 27: (2-((5-Chloro-2-((4-methylbenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0245] [Reaction 27]

[0246]

[0247] To a solution of 4-methylbenzo[d]thiazole-2-amine (31 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (2.8 mg, 0.0048 mmol), cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 °C for 40 min using microwaves. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain compound 27 (40.0 mg, 0.0901 mmol, 56%) as a yellow solid.

[0248] LCMS: 444.0 [M+H]+.

[0249] 1H NMR (300 MHz, CHLOROFORM-d) δ 11.13 (s, 1H), 9.26 (s, 1H), 8.61 (dd, J = 8.5, 4ff.4 Hz, 1H), 8.38 (s, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.60-7.49 (m, 1H), 7.34 (ddd, J = 14.0, 7.7, 1.6 Hz, 1H), 7.26-7.20 (m, 2H), 7.19-7.12 (m, 1H), 2.68 (s, 3H), 1.90 (s, 3H), 1.86 (s, 3H).

[0250] Compound 28: (2-((5-Chloro-2-((6-nitrobenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0251] [Reaction 28]

[0252]

[0253] 2-Amino-6-nitrobenzothiazole (37 mg, 0.19 mmol) solution was added to 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) solution dissolved in dioxane (0.6 ml), and then Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (2.8 mg, 0.0048 mmol), and cesium carbonate (104 mg, 0.32 mmol) were added. The reaction mixture was heated at 160 ° C for 40 minutes using microwaves. The reaction mass was filtered through a celite bed and washed with EA, and the solvent was evaporated under vacuum. The residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain compound 28 (22.0 mg, 0.0463 mmol, 28%) as a yellow solid.

[0254] 1H NMR (300MHz, DMSO-d6) δ12.45 (s, 1H), 11.65 (s, 1H), 8.92 (d, J=2.4Hz, 1H), 8.46 (s, 1H), 8.25 (dd, J=8.9 , 2.5Hz, 1H), 7.79 (d, J=9.0Hz, 1H), 7.71-7.52 (m, 3H), 7.26 (t, J=7.4Hz, 1H), 1.83 (s, 3H), 1.79 (s, 3H).

[0255] Compound 29: (2-((5-Chloro-2-((6-chlorobenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0256] [Reaction 29]

[0257]

[0258] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) was added to a solution of 2-amino-6-chloro-benzothiazole (35 mg, 0.19 mmol) dissolved in dioxane (1 ml), and then Pd(OAc)2 (4.0 mg, 0.016 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (9.2 mg, 0.016 mmol), and cesium carbonate (104 mg, 0.32 mmol) were added. The reaction mixture was heated at 160° C. for 40 minutes using a microwave. The reaction mixture was filtered through a Celite Filter and washed with MeOH, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH in MC to obtain compound 29 (9.4 mg, 12%) as a bright green solid.

[0259] LC / MS: 464.4 [M+H+].

[0260] 1H NMR (400MHz, CDCl3) δ11.07 (s, 1H), 9.55 (s, 1H), 8.49 (dd, J=8.4, 4.3Hz, 1H), 8.31 (s, 1H), 7.75-7 .62 (m, 2H), 7.49 (t, J=7.9Hz, 1H), 7.37-7.28 (m, 2H), 7.23-7.17 (m, 1H), 1.90 (s, 3H), 1.87 (s, 3H).

[0261] Compound 30: (((5-chloropyrimidine-2,4-diyl)bis(azanediyl))bis(2,1-phenylene))bis(dimethylphosphine oxide))

[0262] [Reaction formula 30]

[0263]

[0264] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (10.0 mg, 0.0316 mmol) was added to a 5 mL vial, followed by PTSA (10.8 mg, 0.0569 mmol) and IPA (0.5 ml). The reaction mixture was heated at 130 ° C for 20 minutes using a microwave. The reaction mixture was purified by MPLC using 5% MeOH in MC to obtain compound 30.

[0265] LC / MS: 448.82 [M+H+].

[0266] 1H NMR (400MHz, CDCl3) δ10.96 (s, 1H), 10.60 (s, 1H), 8.75 (dd, J=8.5, 4.5Hz, 1H), 8.64-8.49 (m, 1H), 8.16 (s, 1H), 7.57 (ddt, J=8.7, 7.3, 1.5Hz, 1H), 7.47 (ddt, J= 8.6, 7.3, 1.4Hz, 1H), 7.33-7.29 (m, 1H), 7.28-7.20 (m, 2H), 7.12 (tdd, J=7.5, 2. 4, 1.1Hz, 1H), 7.03 (tdd, J=7.6, 2.4, 1.1Hz, 1H), 1.85 (dd, J=13.1, 4.7Hz, 12H).

[0267] Compound 31: (2-((5-Chloro-2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0268] [Reaction 31]

[0269]

[0270] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) was added to a solution of 2-amino-6-(methylsulfonyl)benzothiazole (43 mg, 0.19 mmol) in dioxane (1 mL), and then Pd(OAc)2 (4.0 mg, 0.016 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (9.2 mg, 0.016 mmol), and cesium carbonate (104 mg, 0.32 mmol) were added. The reaction mixture was heated at 160 ° C for 40 minutes using microwaves. The reaction mixture was filtered through a celite bed filter and washed with MeOH, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH in MC to obtain compound 31 (39.1 mg, 0.0708 mmol, 49%) as a yellow solid.

[0271] LC / MS: 508.3 [M+H+].

[0272] 1H NMR (400MHz, CDCl3) δ11.15 (s, 1H), 11.08 (s, 1H), 8.41 (s, 1H), 8.38-8.33 (m, 1H), 8.29 (d, J=1.9Hz, 1H), 7.97 (d, J=8.5Hz, 1H) , 7.79 (dd, J=8.5, 1.9Hz, 1H), 7.35 (ddd, J=13.9, 7.6, 1.5Hz, 2H), 7.19 (d, J=7.7Hz, 1H), 3.10 (s, 3H), 1.90 (s, 3H), 1.87 (s, 3H).

[0273] Compound 32: (2-((5-Chloro-2-((6-(trifluoromethyl)benzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0274] [Reaction 32]

[0275]

[0276] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol) was added to a solution of 2-amino-6-(trifluoromethyl)benzothiazole (41 mg, 0.19 mmol) in dioxane (1 mL), and then Pd(OAc)2 (4.0 mg, 0.016 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (9.2 mg, 0.016 mmol), and cesium carbonate (104 mg, 0.32 mmol) were added. The reaction mixture was heated at 160 ° C for 20 minutes using a microwave. The reaction mixture was filtered through a diatomaceous earth bed filter and washed with MeOH, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH in MC to obtain compound 32 (14.3 mg, 0.0452 mmol, 18%) as a light brown solid.

[0277] LC / MS: 498.5 [M+H+].

[0278] 1H NMR (400MHz, CDCl3) δ11.08 (s, 1H), 10.91 (s, 1H), 8.42 (dd, J=8.5, 4.3Hz, 1H), 8.38 ( s, 1H), 7.96 (d, J=1.8Hz, 1H), 7.92 (d, J=8.5Hz, 1H), 7.52 (dd, J=8.5, 1.9Hz, 1H), 7.44 -7.28(m, 3H), 7.17(t, J=6.9Hz, 1H), 1.89(s, 3H), 1.85(s, 3H).

[0279] Compound 33: (2-((2-(Benzo[d]thiazol-2-ylamino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0280] [Reaction 33]

[0281]

[0282] To a solution of benzo[d]thiazole-2-amine (38 mg, 0.19 mmol) dissolved in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (2.8 mg, 0.0048 mmol), and cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 °C for 40 minutes using microwaves. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain compound 33 (17 mg, 0.039 mmol, 24%) as a yellow solid.

[0283] LCMS: 413.1 [M+H]+.

[0284] 1H NMR (300 MHz, CHLOROFORM-d) δ 11.50 (s, 1H), 9.42-9.31 (m, 1H), 8.68 (s, 1H), 8.32 (s, 1H), 7.72-7.57 (m, 2H), 7.45 (d, J=8.0 Hz, 1H), 7.31 (t, J=7.7 Hz, 2H), 7.19 (dd, J=12.8, 6.7 Hz, 2H), 1.88 (s, 3H), 1.84 (s, 3H).

[0285] Compound 34: (2-((5-Chloro-2-((6-fluorobenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0286] [Reaction 34]

[0287]

[0288] To a solution of 6-fluorobenzo[d]thiazole-2-amine (32 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (2.8 mg, 0.0048 mmol), cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 °C for 40 min using microwaves. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain compound 34 (31.0 mg, 0.0692 mmol, 43%) as a yellow solid.

[0289] 1H NMR (400MHz, DMSO-d6) δ11.91 (s, 1H), 11.52 (s, 0H), 8.87 (s, 1H), 8.39 (s, 1H), 7.78 (dd, J=8.6, 2 .7Hz, 1H), 7.69-7.61 (m, 2H), 7.58 (t, J=7.9Hz, 1H), 7.30-7.19 (m, 2H), 1.82 (s, 3H), 1.78 (s, 3H).

[0290] Compound 35: (2-((5-Chloro-2-((6-methylbenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0291] [Reaction 35]

[0292]

[0293] To a solution of 6-methylbenzo[d]thiazol-2-amine (32 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (2.8 mg, 0.0048 mmol), cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 °C for 40 min using microwaves. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain compound 35 (46.0 mg, 0.103 mmol, 64%) as a yellow solid.

[0294] 1H NMR (400MHz, DMSO-d6) δ11.79 (s, 1H), 11.46 (s, 1H), 8.85 (s, 1H), 8.38 (s, 1H), 7.70-7.61 (m, 2H), 7.58 (t, 1H), 7 .54 (d, J=8.2Hz, 1H), 7.26 (t, J=7.2Hz, 1H), 7.20 (dd, J=8.4, 1.8Hz, 1H), 2.40 (s, 3H), 1.81 (s, 3H), 1.78 (s, 3H).

[0295] Compound 36: (2-((5-Chloro-2-((6-methoxybenzo[d]thiazol-2-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0296] [Reaction 36]

[0297]

[0298] To a solution of 6-methoxybenzo[d]thiazole-2-amine (33 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (2.8 mg, 0.0048 mmol), cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 °C for 40 min using microwaves. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain compound 36 (46.0 mg, 0.103 mmol, 64%) as a yellow solid.

[0299] 1H NMR (400MHz, chloroform-d) δ11.05 (s, 1H), 9.36 (s, 1H), 8.55 (dd, J=8.4, 4.4Hz, 1H), 8.29 (s, 1H), 7.69 (d, J=8.8Hz, 1H), 7.55-7.46 (m, 1H) , 7.36-7.29 (m, 1H), 7.22 (d, J=2.5Hz, 1H), 7.21-7.15 (m, 1H), 6.98 (dd, J=8.8, 2.6Hz, 1H), 3.86 (s, 3H), 1.87 (s, 3H), 1.84 (s, 3H).

[0300] Compound 37: 5-Fluoro-N 2 ,N 2 -Dimethyl-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 ,N2-dimethyl-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0301] [Reaction 37]

[0302]

[0303] To a solution of compound 20-127 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added 4-amino-8-fluoroquinoline (5-amino-1H-indazole) (22.6 mg, 0.170 mmol), followed by PTSA (46.2 mg, 0.243 mmol). The reaction mixture was heated at 150° C. for 16 hours. The solid was filtered, alkalized with sodium bicarbonate, and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 5% MeOH:MC to obtain yellow solid compound 37 (26.5 mg, 0.0835 mmol, 52%).

[0304] LC / MS: 318.52 [M+H+].

[0305] 1H NMR (400MHz, CDCl3) δ7.76 (d, J=3.4Hz, 1H), 4.66 (d, J=7.3Hz, 1H), 4.06 (tdt, J=11.0, 7.8, 4.1Hz, 1H), 3.86-3.73 (m, 2H) , 3.09 (s, 6H), 2.91 (ddd, J=12.3, 11.1, 2.8Hz, 2H), 2.82 (s, 3H), 2.26-2.14 (m, 2H), 1.66 (dtd, J=12.9, 10.8, 4.1Hz, 2H).

[0306] Compound 38: 5-Fluoro-N 2 -(8-Fluoroquinolin-4-yl)-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 -(8-fluoroquinolin-4-yl)-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0307] [Reaction 38]

[0308]

[0309] To a solution of compound 20-136C (50.0 mg, 0.162 mmol) in dioxane (1 ml) was added 8-fluoroquinolin-4-amine (30.8 mg, 0.194 mmol), followed by the addition of Pd(OAc)2 (3.64 mg, 0.0162 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (9.2 mg, 0.0162 mmol), and cesium carbonate (105 mg, 0.324 mmol). The reaction mixture was heated at 110°C for 20 minutes using a microwave. The reaction mixture was filtered through a celite bed filter and washed with MeOH, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 80% EA (in Hex) to obtain compound 38 (52.4 mg, 0.121 mmol, 74%) as a white solid.

[0310] LC / MS: 435.51 [M+H+].

[0311] 1H NMR (400MHz, CDCl3) δ8.81 (d, J=5.2Hz, 1H), 8.48 (d, J=5.2Hz, 1H), 7.94 (d, J=2.9Hz, 1H) , 7.75 (dt, J=8.4, 1.2Hz, 1H), 7.70 (s, 1H), 7.49 (td, J=8.1, 5.2Hz, 1H), 7.42 (ddd, J=10.2 , 7.8, 1.3Hz, 1H), 5.11-5.00 (m, 1H), 4.21-4.14 (m, 1H), 3.87 (dd, J=10.1, 6.3Hz, 2H), 2. 94 (td, J=12.0, 2.6Hz, 2H), 2.86 (s, 3H), 2.24 (dd, J=13.0, 3.8Hz, 2H), 1.79-1.70 (m, 2H).

[0312] Compound 39: (2-((5-Chloro-2-((3,4-dimethylisoxazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0313] [Reaction 39]

[0314]

[0315] 3,4-Dimethylisoxazol-5-amine (168 mg, 1.50 mmol) was added to a solution of (2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (316 mg, 1.00 mmol) in IPA (3 ml). The reaction mixture was stirred at 90 ° C for 12 hours. After the reaction mixture was cooled to room temperature, it was concentrated to remove IPA. Water was added to the reaction mixture, and the reaction mixture was alkalized with sodium bicarbonate and extracted with DCM. The organic layer was dried over sodium sulfate, and the solvent was evaporated under vacuum. The residue was purified by silica gel column chromatography using 5% MeOH in DCM to obtain compound 39 (220 mg, 0.0696 mmol, 56%) as a white solid.

[0316] LC / MS 392.30 [M+H+].

[0317] 1H NMR (400MHz, CDCl3) δ11.25 (s, 1H), 8.69-8.59 (m, 1H), 8.20 (s, 1H), 7.60-7.58 (m, 1H), 7.34 -7.28(m, 1H), 7.17-7.14(m, 1H), 2.47(s, 3H), 1.87(s, 3H), 1.86-1.85(s, 3H), 1.82(s, 3H).

[0318] Compound 40: (2-((5-Chloro-2-((3,4-dimethylisoxazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide hydrochloride)

[0319] [Reaction 40]

[0320]

[0321] 3,4-Dimethylisoxazol-5-amine (195 mg, 1.74 mmol) was added to a solution of (2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (500 mg, 1.58 mmol) in 0.08 M HCl in ethoxyethanol. The reaction mixture was stirred at 90°C for 8 hours. The reaction mixture was cooled to 0°C using an ice bath, the solid was filtered and washed with 2-ethoxyethanol (3 ml). The solid was dried under high vacuum to give compound 40 (380 mg, 0.970 mmol, 61%) as a white solid.

[0322] LC / MS: 392.51 [M+H+].

[0323] 1H NMR (300MHz, DMSO) δ11.82 (s, 1H), 10.20 (s, br, 2H), 8.60 (s, 1H), 8.43 (m, 1H), 7. 76-7.64(m, 2H), 7.30(m, 1H), 2.65(s, 3H), 1.99(s, 3H), 1.84(s, 3H), 1.82(s, 3H).

[0324] Compound 41: 7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinoline-1(2H)-one

[0325] [Reaction 41]

[0326]

[0327] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (51 mg, 0.16 mmol) in IPA (1 ml) was added 7-amino-3,4-dihydroisoquinolin-1(2H)-one (31 mg, 0.19 mmol), followed by PTSA (30 mg, 0.16 mmol). The reaction mixture was heated overnight at 80°C. The precipitated solid was filtered, washed with EtOH, and dried to obtain compound 41.

[0328] LC / MS(ESI)m / z[M+H]+,[MH]-.

[0329] 1H NMR (300MHz, CDCl3) δ10.94 (s, 1H), 8.64-8.60 (m, 1H), 8.14 (s, 1H), 8.01 (d, J=2.4Hz, 1H), 7.95-7.91 (m, 1H), 7.55-7.49 (m, 1H), 7. 34-7.26 (m, 3H), 7.20-7.11 (m, 1H), 6.14 (s, 1H), 3.61-3.56 (m, 2H), 3.51 (s, 1H), 2.99 (t, J=6.6Hz, 2H), 1.88 (s, 3H), 1.835 (s, 3H).

[0330] Compound 42: 1-(7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0331] [Reaction 42]

[0332]

[0333] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (51 mg, 0.16 mmol) in IPA (1 mL) was added 1-(7-Amino-1,1-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one (52 mg, 0.19 mmol), and then PTSA (30 mg, 0.16 mmol) was added. The reaction mixture was heated at 80° C. overnight. The precipitated solid was filtered, washed with EtOH, and dried to obtain compound 42.

[0334] LC / MS(ESI)m / z[M+H]+,[MH]-.

[0335] 1H NMR (300MHz, CDCl3) δ10.88 (s, 1H), 8.57-8.53 (m, 1H), 8.57-8.53 (m, 1H), 8.14 (s, 1H), 7.52-7.46 (m, 2H), 7.41 (d, J=2.1Hz, 1H), 7.35-7.30 ( m, 1H), 7.18-7.12 (m, 1H), 7.07 (d, J=8.1Hz, 1H), 7.00 (s, 1H), 3.67 (t, J=3Hz, 2H), 2.88 (t, J=6Hz, 2H), 1.88 (s, 3H), 1.84 (s, 3H), 1.79 (s, 6H).

[0336] Compound 43: 1-(7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)(ethyl)amino)-1,1-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0337] [Reaction 43]

[0338]

[0339] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (51 mg, 0.16 mmol) in IPA (1 mL) was added 1-(7-(ethylamino)-1,1-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one (57 mg, 0.19 mmol), followed by PTSA (30 mg, 0.16 mmol). The reaction mixture was heated at 80° C. overnight. The precipitated solid was filtered, washed with EtOH, and dried to obtain compound 43.

[0340] LC / MS (ESI) m / z 580.2 [M+H]+.

[0341] 1H NMR (300MHz, CDCl3) δ10.9 (s, br, 1H), 8.27-8.26 (m, 1H), 8.06 (s, 1H), 7.23-6.99 (m, 6H), 3.99 (q, J=7.0Hz , 2H), 3.72-3.70 (m, 2H), 2.99-2.96 (m, 2H), 1.85 (s, 3H), 1.80 (s, 3H), 1.77 (s, 6H), 1.28 (t, J=7.2Hz, 3H).

[0342] Compound 44: (2-((5-Chloro-2-((1,1-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide)

[0343] [Reaction 44]

[0344]

[0345] To a solution of compound 018 (14 mg, 0.03 mmol) dissolved in THF (2 ml), MeOH (1 ml) and H2O (0.5 ml) was added lithium hydroxide monohydrate (2.5 mg, 0.06 mmol) at room temperature, and the reaction mixture was stirred for 2 hours at room temperature. The precipitated solid was filtered, washed with EtOH, and dried to obtain compound 44.

[0346] LC / MS (ESI) m / z 456.2 [M+H]+.

[0347] 1H NMR (300MHz, CDCl3) δ11.2 (s, br, 1H), 9.30 (s, br, 1H), 8.50 (s, 1H), 8.29 (s, 1H), 7.70-7.49 (m, 4H), 7.40 (s, 1H), 7 .19-7.10 (m, 1H), 6.85-6.80 (m, 1H), 2.90-2.85 (m, 2H), 2.68-2.59 (m, 2H), 1.85 (s, 3H), 1.80 (s, 3H), 1.35 (s, 6H).

[0348] Compound 45: (2-((5-Chloro-2-((2-(5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0349] [Reaction 45]

[0350]

[0351] To a solution of 1,2,3,4-tetrahydroisoquinolin-5-amine (28 mg, 0.19 mmol) in IPA (0.6 mL) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (36 mg, 0.19 mmol). The reaction mixture was heated overnight at 80 °C. TLC showed the formation of a new spot, the reaction was quenched with sodium bicarbonate and extracted with DCM (20 ml x 2), the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as a solvent mixture and purified by MPLC to obtain compound 45 (9.0 mg, 0.0127 mmol, 8%) as a brown solid.

[0352] LCMS: 707.2 [M+H]+.

[0353] LCMS: 1H NMR (300 MHz, chloroform-d) δ 11.12 (s, 1H), 10.81 (s, 1H), 8.65 (dd, J = 8.6, 4.4 Hz, 1H), 8.47 (dd, J = 8.6, 4.7 Hz, 1H), 8.06 (d, J = 9.8 Hz, 2H), 7.64-7.50 (m, 2H), 7.33 (dd, J = 7.8, 1 .4Hz, 1H), 7.26-7.05(m, 5H), 7.05-6.97(m, 1H), 6.81(s, 1H), 4.95(s, 2H), 4.00(t , J=5.9Hz, 2H), 2.88 (t, J=5.9Hz, 2H), 1.86 (d, J=9.8Hz, 6H), 1.81 (d, J=9.8Hz, 6H).

[0354] Compound 46: 1-(7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0355] [Reaction 46]

[0356]

[0357] 1) Synthesis of 2,2,2-trifluoro-N-(4-nitrophenethyl)acetamide

[0358] Trifluoroacetic anhydride (TFAA) (26.0 g, 124 mmol) was added to a solution of 2-(4-nitrophenyl)ethane-1-amine (10.0 g, 49.5 mmol) in DCM (200 ml) at room temperature. Triethylamine (TEA) (13.0 g, 124 mmol) was added to an ice bath using a dropping funnel and stirred at room temperature until the reaction was complete. TLC showed that the starting material was consumed. The reaction was quenched with 30 ml of water and extracted with DCM / water. The DCM layer was washed with 100 ml of 1N HCl (aqueous). The DCM layer was then dried with sodium sulfate and the solvent was evaporated under vacuum to obtain compound 20-001 (14.0 g, 53.4 mmol, crude product (crude)>100%) as an ivory solid.

[0359] *The product was not purified and was carried on to the next step.

[0360] 1H NMR (400MHz, CDCl3) δ 8.18 (d, J=8.1Hz, 2H), 7.37 (d, J=8.1Hz, 2H), 6.53 (s, br, 1H), 3.67 (q, J=6.9Hz, 2H), 3.02 (t, J=7.1Hz, 2H).

[0361] 2) Synthesis of 2,2,2-trifluoro-1-(7-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one

[0362] At 0°C, a 250ml round-bottom flask (RB) was filled with 50ml of acetic acid and 75ml of sulfuric acid. Compound 20-001 (13.0g, 79.4mmol) and paraformaldehyde (0.183g, 6.11mmol) were added to the solution. The temperature was raised to 35°C and stirred until the reaction was complete. TLC showed that the reaction was complete, and the reaction mixture was carefully poured into water for dilution. Subsequently, the aqueous layer was extracted with EtOAc (250ml×2). The organic layer was dried over sodium sulfate, and the solvent was evaporated under vacuum to obtain compound 20-004 (11.0g, 42.0mmol, 75%) as a white solid.

[0363] 1H NMR (400MHz, CDCl3) δ8.08 (q, J=9.0, 7.6Hz, 2H), 7.44-7.29 (m, 1H), 4.88 (d, J=17.8Hz, 2H), 4.01 -3.81 (m, 2H), 3.08 (t, J=6.5Hz, 2H).

[0364] 3) Synthesis of 1-(7-amino-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0365] To a solution of compound 20-004 (11.0 g, 40.1 mmol) in EA (50 ml) was added 10% Pd / C (1.10 g) using a parr reactor at 35 psi. After removing Pd / C using a celite bed filter, the filtrate was concentrated to give compound 20-006 (9.20 g, 37.7 mmol, 95%) as an ivory solid.

[0366] 1H NMR (400MHz, CDCl3) δ6.95 (t, J=8.6Hz, 1H), 6.57 (t, J=8.7Hz, 1H), 6.45 (d, J=13.1 Hz, 1H), 4.66 (d, J=22.0Hz, 2H), 3.82 (d, J=18.8Hz, 2H), 3.64 (s, 2H), 2.84 (s, 2H).

[0367] 4) Synthesis of 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one

[0368] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (100 mg, 0.316 mmol) to a 7 mL vial, compound 20-006 (81.2 mg, 0.332 mmol), PTSA (90.3 mg, 0.475 mmol), IPA (1 ml) were added. The reaction mixture was heated overnight at 95 ° C. The reaction was quenched with sodium bicarbonate and extracted with DCM (50 ml × 2), the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. The crude mixture was purified by MPLC using 5% MeOH:DCM to obtain compound 46 (58.6 mg, 37.7 mmol, 95%) as an ivory solid.

[0369] 1H NMR (400MHz, CDCl3) δ10.92 (d, J=8.4Hz, 1H), 8.54 (d, J=7.3Hz, 1H), 8.21-8.07 (m, 1H), 7.57 (dd, J=26.9, 21.2Hz, 2H), 7.34 (dd, J=14.4, 7.9Hz, 1H ), 7.27-7.01(m, 3H), 6.98(s, 1H), 4.72(d, J=13.8Hz, 2H), 3.99-3.75(m, 2H), 2.95 (t, J=6.9Hz, 2H), 1.89 (d, J=2.3Hz, 3H), 1.85 (d, J=2.4Hz, 3H).

[0370] Compound 47: (2-((5-Chloro-2-((1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0371] [Reaction 47]

[0372]

[0373] To a solution of compound 20-007 (46.6 mg, 0.0764 mmol) in THF / MeOH / water (2:1:0.5) (1 ml) was added LiOH·H2O (24.1 mg, 0.572 mmol) at room temperature. After 30 hours, the solvent was concentrated using a rotary evaporator and EA / MC was added. The solid was removed using a syringe filter. After acid / base operation, the filtrate was crushed and purified to obtain compound 47 (11.0 mg, 0.0257 mmol, 34%) as a white solid.

[0374] LC / MS: 426.19 [M+H]+.

[0375] 1H NMR (400MHz, CDCl3) δ10.87 (s, 1H), 8.58 (dt, J=7.4, 3.4Hz, 1H), 8.08 (d, J=2.4Hz, 1H), 7.48 (t, J=8.1Hz, 1H), 7.27 (d, J=7.8Hz, 2H), 7.24 (d, J= 7.9Hz, 1H), 7.12 (t, J=7.7Hz, 1H), 7.08-6.94 (m, 2H), 3.97 (s, 2H), 3.15 (dt, J=6.1, 3.7Hz, 2H), 2.79 (d, J=6.2Hz, 2H), 1.85 (s, 1H), 1.82 (s, 3H).

[0376] Compound 48: 1-(6-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinoline-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0377] [Reaction 48]

[0378]

[0379] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50.0 mg, 0.316 mmol) to a 5 mL vial, compound 16-321 (40.6 mg, 0.166 mmol), PTSA (45.1 mg, 0.237 mmol), and IPA (0.5 ml) were added. The reaction mixture was heated at 100 ° C for 5 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (50 ml × 2) and water. The organic layer was dried over sodium sulfate, and the solvent was distilled under vacuum. The mixture was purified by MPLC using 4% to 9% MeOH in MC (gradient) to obtain compound 48 (35.8 mg, 0.06835 mmol, 43%) as a white and light pink solid.

[0380] 1H NMR (400MHz, CDCl3) δ10.98 (s, 1H), 8.67-8.53 (m, 1H), 8.14 (d, J=0.8Hz, 1H), 7.55-7.44 (m, 2H), 7.43-7.29 (m, 2H), 7.17 (dddd, J=8.6, 7.5, 2.3, 1.1 Hz, 1H), 7.09 (dd, J=14.8, 8.3Hz, 1H), 6.98 (d, J=7.3Hz, 1H), 4.76 (d, J=18 .4Hz, 2H), 3.96-3.81(m, 2H), 3.00-2.86(m, 2H), 1.89(s, 3H), 1.84(s, 3H).

[0381] Compound 49: (2-((5-Chloro-2-((1,2,3,4-tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0382] [Reaction 49]

[0383]

[0384] At room temperature, LiOH·H2O (2.0 mg, 0.0477 mmol) was added to a solution of compound 20-029 (7.0 mg, 0.0134 mmol) dissolved in THF / MeOH / water (2:1:0.5) (1 ml). After 30 minutes, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and NaOH to obtain compound 49 (5.5 mg, 0.0105 mmol, 96%) as a white solid.

[0385] 1H NMR (400MHz, CDCl3) δ10.90 (s, 1H), 8.65-8.57 (m, 1H), 8.09 (s, 1H), 7.51-7.44 (m, 1H), 7.34-7.27 (m, 3H), 7.16-7.08 (m, 1H) ), 6.95 (d, J=8.1Hz, 1H), 6.85 (s, 1H), 4.00 (s, 2H), 3.14 (t, J=5.9Hz, 2H), 2.76 (t, J=6.0Hz, 2H), 1.87 (s, 3H), 1.84 (s, 3H).

[0386] Compound 50: 1-(7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4,4-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0387] [Reaction 50]

[0388]

[0389] After adding compound 17-039 (2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine) (47.0 mg, 0.149 mmol) to a 7 mL vial, 1-(7-(amino)-4,4-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one (42.1 mg, 0.156 mmol), PTSA (54.2 mg, 0.285 mmol), and IPA (0.5 ml) were added. The reaction mixture was heated at 95° C. for 4 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (50 ml×2) and water, the organic layer was dried over sodium sulfate, and the solvent was distilled under vacuum. The mixture was purified by MPLC using 3% to 7% MeOH in DCM (gradient) to obtain compound 50 (35.8 mg, 0.0648 mmol, 44%) as a white solid.

[0390] LC / MS: 552.6 [M+H+].

[0391] 1H NMR (400MHz, CDCl3) δ10.90 (d, J=15.7Hz, 1H), 8.59-8.43 (m, 1H), 8.11 (d, J=3.6Hz, 1H), 7.65-7.41 (m, 2H), 7.37-7.27 (m, 2H), 7.26-7.1 2 (m, 2H), 6.97 (d, J=4.0Hz, 1H), 4.72 (d, J=4.0Hz, 2H), 3.67 (s, 1H), 3.59-3.48 (m, 1H), 1.88 (s, 3H), 1.83 (s, 3H), 1.30 (d, J=2.9Hz, 6H).

[0392] Compound 51: (2-((5-Chloro-2-((1-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0393] [Reaction 51]

[0394]

[0395] LiOH·H2O (5.55 mg, 0.132 mmol) was added to a solution of compound 20-035 (20.0 mg, 0.0370 mmol) in THF / MeOH / water (2:1:0.5) (0.5 ml) at room temperature. After 30 minutes, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and NaOH to obtain compound 51 (11.3 mg, 0.0210 mmol, 69%) as a white solid.

[0396] LC / MS: 442.5 [M+H+].

[0397] 1H NMR (400MHz, CDCl3) δ10.87 (s, 1H), 8.61-8.56 (m, 1H), 8.10 (s, 1H), 7.51-7.45 (m, 1H), 7.35 (dd, J=8.2, 2 .3Hz, 1H), 7.30 (td, J=7.2, 6.7, 2.0Hz, 2H), 7.26 (s, 1H), 7.12 (tdd, J=7.6, 2.4, 1.1Hz, 1H), 7.03 (d, J=8.2 Hz, 1H), 6.86 (s, 1H), 4.08 (q, J=6.6Hz, 1H), 3.28 (dt, J=12.6, 5.0Hz, 1H), 3.02 (ddd, J=12.9, 8.9, 4.7Hz, 1H), 2.89-2.78 (m, 1H), 2.71 (dt, J=16.1, 4.6Hz, 1H), 1.84 (dd, J=13.1, 5.8Hz, 6H), 1.37 (d, J=6.6Hz, 3H).

[0398] Compound 52: (2-((5-Chloro-2-((4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0399] [Reaction 52]

[0400]

[0401] LiOH·H2O (2.71 mg, 0.0645 mmol) was added to a solution of compound 20-036 (10.0 mg, 0.0181 mmol) in THF / MeOH / water (2:1:0.5) (0.5 ml) at room temperature. After 30 minutes, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and NaOH to obtain compound 52 (7.78 mg, 0.0171 mmol, 94%) as a white solid.

[0402] LC / MS: 456.6 [M+H+].

[0403] 1H NMR (400MHz, CDCl3) δ10.89 (s, 1H), 8.59 (ddd, J=8.5, 4.4, 1.1Hz, 1H), 8.09 (d, J=3.8Hz, 1H), 7.48 (dd, J=8.6, 7.2Hz, 1H), 7.33-7. 27 (m, 1H), 7.25 (d, J=1.5Hz, 2H), 7.17-7.08 (m, 1H), 6.90 (s, 1H), 3.96 (s, 2H), 2.86 (s, 2H), 1.85 (s, 3H), 1.82 (s, 3H) 1.27 (s, 6H).

[0404] Compound 53: 1-(7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0405] [Reaction 53]

[0406]

[0407] Compound 18-012 (2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine) (50 mg, 0.16 mmol) was added to a solution of 1-(7-(amino)-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one (45 mg, 0.19 mmol) dissolved in dioxane (1 ml), and then Pd(OAc)2 (4.0 mg, 0.016 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (9.2 mg, 0.016 mmol), and cesium carbonate (104 mg, 0.32 mmol) were added. The reaction mixture was heated at 160° C. for 40 minutes using a microwave. The reaction mixture was filtered through a celite bed filter and washed with MeOH, the solvent was evaporated under vacuum and the residue was purified by MPLC using 5% MeOH in MC to give Compound 53 (14.8 mg, 0.0262 mmol, 16%) as a yellow-green solid.

[0408] LC / MS: 566.7 [M+H+].

[0409] 1H NMR (300MHz, DMSO) δ11.02 (s, 1H), 9.46 (s, 1H), 8.30 (s, 1H), 8.19 (d, J = 2.3Hz, 1H), 7.69-7.55 (m, 3H), 7.46 (d, J = 9.4Hz, 1H), 7.21 ( s, 1H), 7.06 (d, J=8.4Hz, 1H), 4.93 (d, J=9.5Hz, 1H), 3.97-3.68 (m, 2H), 2.90 (d, J=6.8Hz, 2H), 1.92-1.58 (m, 6H), 0.89-0.74 (m, 6H).

[0410] Compound 54: 1-(7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0411] [Reaction 54]

[0412]

[0413] After adding compound 17-045 (2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine) (50.0 mg, 0.316 mmol) to a 5 mL vial, 1-(7-(amino)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one (42.9 mg, 0.166 mmol), PTSA (54.2 mg, 0.285 mmol), and IPA (0.5 ml) were added. The reaction mixture was heated at 100°C for 4 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (50 ml×2) and water, the organic layer was dried over sodium sulfate, and the solvent was distilled under vacuum. The mixture was purified by MPLC using 3% to 7% MeOH in CM (gradient) to obtain compound 54 (63.6 mg, 0.118 mmol, 75%) as a white solid.

[0414] 1H NMR (300MHz, CDCl3) δ10.83 (s, 1H), 8.49 (dd, J=8.4, 4.4Hz, 1H), 8.11 (s, 1H), 7. 64-7.41 (m, 2H), 7.37-7.27 (m, 1H), 7.25-7.11 (m, 2H), 7.06 (dd, J=8.4, 4.4Hz, 1H ), 6.93 (s, 1H), 5.50 (q, J=6.8Hz, 1H), 4.13-3.98 (m, 1H), 3.67-3.46 (m, 1H), 3.0 9-2.90 (m, 1H), 2.81 (d, J=16.2Hz, 1H), 1.93-1.74 (m, 6H), 1.39 (d, J=6.6Hz, 3H).

[0415] Compound 55: (2-((5-Chloro-2-((1-isopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0416] [Reaction 55]

[0417]

[0418] LiOH·H2O (2.6 mg, 2.55 mmol) was added to a solution of compound 20-050 (9.7 mg, 0.0177 mmol) in THF / MeOH / water (2:1:0.5) (1 ml) at room temperature. After 6 hours, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and NaOH to obtain compound 55 (1.9 mg, 0.00213 mmol, 14%) as a light yellow solid.

[0419] LC / MS: 468.95 [M+H+].

[0420] 1H NMR (400MHz, CDCl3) δ10.87 (s, 1H), 8.58 (dd, J=8.6, 4.4Hz, 1H), 8.10 (s, 1H), 7.51-7.44 (m, 1H), 7.38-7.27 ( m, 3H), 7.12 (tdd, J=7.6, 2.4, 1.1Hz, 1H), 7.02 (d, J=8.2Hz, 1H), 6.85 (s, 1H), 3.90 (d, J=3.7Hz, 1H), 3.30 (dd d, J=11.9, 5.2, 3.1Hz, 1H), 2.92 (ddd, J=11.9, 10.3, 4.0Hz, 1H), 2.86-2.74 (m, 1H), 2.65 (d, J=15.7Hz, 1H), 2 .20 (ddd, J=9.5, 6.7, 3.2Hz, 1H), 1.84 (dd, J=13.1, 8.1Hz, 6H), 1.05 (d, J=6.9Hz, 3H), 0.71 (d, J=6.8Hz, 3H).

[0421] Compound 56: 2,2,2-Trifluoro-1-(7-((5-fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one

[0422] [Reaction 56]

[0423]

[0424] 1) tert-butyl4-((2-chloro-5-fluoropyrimidin-4-yl)amino)piperidine-1-carboxylate

[0425] 2,4-Dichloro-5-fluoropyrimidine (2,4-Dichloro-5-fluoropyrimidine) (800mg, 4.80mmol), tert-Butyl4-aminopiperidine-1-carboxylate (tert-Butyl4-aminopiperidine-1-carboxylate) (996mg, 4.80mmol) and N,N-diisopropylethylamine (DIPEA) (948μL, 5.76mmol) were dissolved in tetrahydrofuran (THF) (30ml). The reaction mixture was heated overnight under reflux conditions. After cooling, the EA layer was separated by water / EA, dried over sodium sulfate, and the solvent was removed by rotary evaporation. The reaction mixture was purified by silica gel column chromatography using 30% EA in hexane (Hex) to obtain compound 20-098b (1.33g, 4.02mmol) as a white solid.

[0426] 1H NMR (400MHz, CDCl3) δ7.81 (d, J=2.8Hz, 1H), 5.64 (dd, J=8.0, 2.2Hz, 1H), 4.13 (ddq, J=11.0, 7.2, 3.8Hz, 1H) , 4.13-4.01 (m, 2H), 2.87 (t, J=12.9Hz, 2H), 2.10-1.90 (m, 2H), 1.48-1.43 (m, 1H), 1.41 (s, 9H), 1.39 (s, 1H).

[0427] 2) 2-chloro-5-fluoro-N-(piperidin-4-yl)pyrimidin-4-amine

[0428] To a solution of compound 20-098b (600 mg, 1.81 mmol) in DCM (20 ml) at 0°C was added dioxane (1.80 mL, 3.62 mmol) containing 4N HCl. The resulting mixture was stirred for 6 hours at room temperature, and trifluoroacetic acid (TFA) (4 ml) was added and stirred for 1 hour. The reaction was evaporated and extracted with DCM. The aqueous layer was alkalized with sodium bicarbonate and extracted with DCM. The combined organic layers were dried over Na2SO4 and the solvent was removed under vacuum to obtain compound 20-101 (415 mg, 1.80 mmol, 98%) as a white solid.

[0429] 1H NMR (400MHz, CDCl3) δ7.87 (d, J=2.8Hz, 1H), 5.15-4.97 (m, 1H), 4.19-4.05 (m, 1H), 3.12 (dt, J=13.3, 4. 1Hz, 2H), 2.78 (ddd, J=12.7, 11.4, 2.6Hz, 2H), 2.11-2.02 (m, 2H), 1.42 (dtd, J=12.5, 11.2, 4.0Hz, 2H).

[0430] 3) 2-chloro-5-fluoro-N-(1-(methylsulfonyl)piperidin-4-yl)pyrimidin-4-amine

[0431] After dissolving compound 20-101 (360 mg, 1.56 mmol) in DCM (50 ml), cool it at 0 ° C. Add DIPEA (2.69 ml, 15.6 mmol) to the solution and stir for 10 minutes. After 10 minutes, add methanesulfonyl chloride (241 μL, 3.12 mmol), warm to room temperature, and stir for 20 minutes. The reaction mixture was extracted with DCM (100 ml×2) and washed with brine (50 ml). The combined organic layer was dried with Na2SO4, and the solvent was removed under vacuum. The reaction mixture was crushed and purified with EA and hexane (hex) to obtain compound 20-105 (418 mg, 1.35 mmol, 87%) as a yellow solid.

[0432] 1H NMR (500MHz, CDCl3) δ7.93 (d, J=2.7Hz, 1H), 5.24 (d, J=8.0Hz, 1H), 4.19 (tdt, J=11.7, 8.2, 4.2Hz, 1H), 3 .94-3.83 (m, 2H), 2.92 (td, J=12.2, 2.6Hz, 2H), 2.25-2.17 (m, 2H), 1.70 (dtd, J=12.9, 11.5, 4.2Hz, 2H).

[0433] 4) 2,2,2-Trifluoro-1-(7-((5-fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one

[0434] To a solution of compound 20-105 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added HYP-19 (41.5 mg, 0.170 mmol), followed by PTSA (55.4 mg, 0.243 mmol). The reaction mixture was heated at 90°C for 6 hours. The solid was filtered, basified with sodium bicarbonate, and purified with DCM. The reaction mixture was purified by silica gel column chromatography using 5% MeOH in DCM to obtain compound 56 (38.8 mg, 0.0751 mmol, 46%) as a white solid.

[0435] LC / MS: 518.27 [M+H+].

[0436] 1H NMR (400MHz, DMSO) δ9.09 (d, J=11.7Hz, 1H), 7.90 (d, J=3.7Hz, 1H), 7.72 (d, J=55.9Hz, 1H), 7.50-7.33 (m, 2H), 7.08 (t, J=8.0Hz, 1H), 4.72 (s, 2H), 4.11 -3.99 (m, 1H), 3.81 (s, 2H), 3.65 (d, J = 11.7Hz, 2H), 2.91 (d, J = 6.7Hz, 3H), 2 .84 (d, J=10.8Hz, 4H), 2.02 (d, J=12.0Hz, 2H), 1.67 (tt, J=12.3, 6.3Hz, 2H).

[0437] Compound 57: 5-Fluoro-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)-N 2 -(1,2,3,4-Tetrahydroisoquinolin-7-yl)pyrimidine-2,4-diamine (5-Fluoro-N 4-(1-(methylsulfonyl)piperidin-4-yl)-N 2 -(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrimidine-2,4-diamine)

[0438] [Reaction 57]

[0439]

[0440] At room temperature, LiOH·H2O (7.68 mg, 0.183 mmol) was added to a solution of compound 20-110 (27.0 mg, 0.0523 mmol) dissolved in THF / MeOH / water (2:1:0.5) (7 ml). After 1 hour, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and 1N NaOH to obtain compound 57 (22.0 mg, 0.0523 mmol, 99%) as a white solid.

[0441] LC / MS: 421.33 [M+H+].

[0442] 1H NMR (500MHz, CDCl3) δ7.83 (d, J=3.2Hz, 1H), 7.27 (s, 1H), 7.04 (d, J=8.0Hz, 1H), 6.74 (s, 1H), 4.83 (d, J=7.5Hz, 1H), 4.15-4.07 (m, 1H), 4.03 (s, 2H), 3.8 6 (d, J=12.5Hz, 2H), 3.17 (t, J=6.0Hz, 2H), 2.94 (td, J=12.0, 2.7Hz, 2H), 2. 87 (s, 3H), 2.78 (t, J=6.0Hz, 2H), 2.24 (d, J=13.6Hz, 2H), 1.76-1.66 (m, 2H).

[0443] Compound 58: 2,2,2-Trifluoro-1-(7-((5-fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidin-2-yl)amino)-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one

[0444] [Reaction 58]

[0445]

[0446] To a solution of compound 20-105 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added 1-(7-(amino)-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one (48.7 mg, 0.170 mmol), and then PTSA (46.2 mg, 0.243 mmol) was added. The reaction mixture was heated at 90° C. for 4 hours. The reaction mixture was basified with sodium bicarbonate and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 5% MeOH in DCM to obtain compound 58 (47.9 mg, 0.0236 mmol, 54%) as a white solid.

[0447] LC / MS: 560.33 [M+H+].

[0448] 1H NMR (400MHz, CDCl3) δ7.81 (d, J=3.2Hz, 1H), 7.73 (d, J=2.1Hz, 1H), 7.12-7.03 (m, 2H), 6.84 (s, 1H), 5.18 (d, J=9.3Hz, 1H), 4.85 (d, J=7.7Hz, 1H), 4.13 (tdt, J=11.6, 8.2, 4.2Hz, 1H), 4.05-3.89 (m, 2H), 3.88-3.74 (m, 2H), 3.07 (td, J=11.9, 2.6Hz, 1 H), 3.00-2.94 (m, 2H), 2.92 (d, J=2.7Hz, 1H), 2.91 (s, 3H), 2.29-2.17 (m, 3H), 2.14 -2.03 (m, 1H), 1.76-1.62 (m, 2H), 1.04 (d, J=6.6Hz, 3H), 0.98 (d, J=6.8Hz, 3H).

[0449] Compound 59: 2,2,2-Trifluoro-1-(7-((5-fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidin-2-yl)amino)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one

[0450] [Reaction 59]

[0451]

[0452] To a solution of compound 20-105 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added 1-(7-(amino)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one (43.9 mg, 0.170 mmol), and then PTSA (46.2 mg, 0.243 mmol) was added. The reaction mixture was heated at 90° C. for 12 hours. The reaction mixture was basified with sodium bicarbonate and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 5% MeOH in DCM to obtain compound 59 (63.2 mg, 0.119 mmol, 74%) as a white solid.

[0453] LC / MS: 531.31 [M+H+].

[0454] 1H NMR (400MHz, CDCl3) δ7.82 (dd, J=4.9, 3.2Hz, 1H), 7.69 (d, J=2.2Hz, 1H), 7.11 (dd, J=8.3, 2.3Hz, 1H), 7. 04 (d, J=8.2Hz, 1H), 6.80 (d, J=18.4Hz, 1H), 5.55 (q, J=6.9Hz, 1H), 4.86 (d, J=7.6Hz, 1H), 4.19-4.09 (m, 1H), 4.09-4.01(m, 1H), 3.89(dd, J=21.3, 12.5Hz, 3H), 3.68-3.55(m, 1H), 3.04-2.93(m, 2H), 2.91(s, 3H ), 2.89-2.78 (m, 3H), 2.23 (t, J=16.5Hz, 2H), 1.71 (ddt, J=19.1, 12.8, 6.0Hz, 2H), 1.54 (d, J=6.9Hz, 3H).

[0455] Compound 60: 5-Fluoro-N 2 -(1-isopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 -(1-isopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0456] [Reaction 60]

[0457]

[0458] To a solution of compound 20-117 (27.0 mg, 0.0523 mmol) dissolved in THF / MeOH / water (2:1:0.5) (7 ml) was added LiOH·H2O (7.68 mg, 0.183 mmol) at 40° C. After 6 hours, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and 1N NaOH to obtain compound 60 (19.4 mg, 0.0523 mmol, 78%) as a white solid.

[0459] LC / MS: 464.33 [M+H+].

[0460] 1H NMR (400MHz, CDCl3) δ7.80 (d, J=3.2Hz, 1H), 7.35 (dd, J=8.3, 2.3Hz, 1H), 7.28 (d, J=2.3Hz, 1H), 7.00 (d, J=8.2Hz, 1H), 6.83 (s, 1H), 4.85 (dd, J=7.9, 2.2Hz, 1H), 4.09 (dt, J=7.3, 3.8Hz, 1H), 3.93 (d, J=3.7Hz, 1H), 3.87-3.77 (m, 2H), 3.29 (ddd, J=11 .9, 5.2, 3.1Hz, 1H), 2.91 (dddd, J=11.8, 10.2, 5.7, 3.2Hz, 3H), 2.78 (td, J=10.3, 3.7Hz, 1H), 2.63 (dt, J=15.7, 3.5Hz, 1H), 2.32 (td, J=6.9, 3.8Hz, 1H), 2.19 (dt, J=11.3, 3.4Hz, 2H), 1.68-1.58 (m, 2H), 1.13 (d, J=6.9Hz, 3H), 0.76 (d, J=6.7Hz, 3H).

[0461] Compound 61: 5-Fluoro-N 2 -(1-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 -(1-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0462] [Reaction 61]

[0463]

[0464] LiOH·H2O (7.36 mg, 0.185 mmol) was added to a solution of compound 20-118 (28.0 mg, 0.0528 mmol) dissolved in THF / MeOH / water (2:1:0.5) (7 ml) at 40°C. The reaction mixture was then stirred for 6 hours, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and 1N NaOH to obtain compound 61 (17.6 mg, 0.0528 mmol, 80%) as a white solid.

[0465] LC / MS: 435.31 [M+H+].

[0466] 1H NMR (500MHz, DMSO) δ8.87 (s, 1H), 7.88 (d, J = 3.7Hz, 1H), 7.48 (d, J = 2.2Hz, 1H), 7.43 (dd, J = 8.3, 2.2Hz, 1H), 7.35 (d, J=7.9Hz, 1H), 6.92 (d, J=8.3Hz, 1H), 4.06 (d, J=7.4Hz, 1H), 3.90 (d, J=6.8Hz, 1H), 3.67-3.59 (m, 2H ), 3.39 (d, J=7.0Hz, 2H), 3.06 (dt, J=10.4, 5.0Hz, 1H), 2.92 (s, 3H), 2.83 (d, J=12.0Hz, 2H), 2.76 (d, J=4.4H z, 1H), 2.70-2.63 (m, 1H), 2.56 (s, 1H), 1.99 (d, J=12.5Hz, 2H), 1.66 (t, J=6.2Hz, 2H), 1.33 (d, J=6.6Hz, 3H).

[0467] Compound 62: 1-(7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one

[0468] [Reaction 62]

[0469]

[0470] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (30.0 mg, 0.0949 mmol) in IPA (2.0 ml) was added compound VP-20-318 (26.0 mg, 0.0949 mmol), followed by PTSA (36.0 mg, 0.189 mmol). The reaction mixture was heated overnight at 90°C. TLC showed the formation of new spots, the solid was filtered, dissolved in water, alkalized with sodium bicarbonate at pH 7-8, washed with 10 ml of MC, extracted with DCM (20 ml x 2), and the organic layer was dried. Sodium sulfate and solvent were distilled under vacuum, and the residue was purified by MPLC using 5% MeOH:MC to obtain off-white flocculent compound 62 (28.0 mg, 0.0505 mmol, 53%).

[0471] 1H NMR (500MHz, chloroform-d) δ10.79 (d, J=7.4Hz, 1H), 8.49 (dd, J=8.3, 4.1Hz, 1H), 8 .21(s, 1H), 8.19-8.16(m, 1H), 8.15(s, 1H), 7.68-7.59(m, 2H), 7.59-7.53 (m, 1H), 7.39-7.33 (m, 1H), 6.68-6.63 (m, 1H), 4.66-4.57 (m, 2H), 3.93-3. 83 (m, 5H), 2.96-2.88 (m, 2H), 1.88 (d, J=1.7Hz, 3H), 1.86 (d, J=1.7Hz, 3H).

[0472] Compound 63: (2-((5-Chloro-2-((6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0473] [Reaction 63]

[0474]

[0475] At room temperature, LiOH·H2O (5.4 mg, 0.126 mmol) was added to a solution of compound 20-326 (28.0 mg, 0.0505 mmol) in THF:MeOH:H2O (2:10:0.5), and stirred for 12 hours. TLC confirmed that the reaction was complete. The solvent was evaporated, and the residue was acidified with 1N HCl (aq), washed with MC (20 ml × 2), the aqueous layer was alkalized with solid sodium bicarbonate, and the aqueous layer was extracted with DCM (20 ml × 2), and the combined organic layer was dried with sodium sulfate and filtered. Under vacuum conditions, the solvent was evaporated to obtain a slightly white brown solid compound 63 (16 mg, 0.0349 mmol, 9%).

[0476] LCMS: 458.2 [M+H]+.

[0477] 1H NMR (500MHz, chloroform-d) δ10.79 (s, 1H), 8.58 (dd, J=8.4, 4.3Hz, 1H), 8.13 (s, 1H), 7.99 (s, 1H), 7.59-7.51 (m, 2H), 7.32 (ddd, J=14.0, 7.7, 1.6Hz, 1H), 7 .20-7.13(m, 1H), 6.61(s, 1H), 3.90(d, J=3.2Hz, 2H), 3.89(s, 2H), 3.18- 3.11 (m, 2H), 2.77 (t, J=6.0Hz, 2H), 2.20 (s, 1H), 1.86 (d, J=13.2Hz, 6H).

[0478] Compound 64: (2-((2-((1H-Indazol-6-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0479] [Reaction 64]

[0480]

[0481] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol) was added to a solution of 1H-indazol-6-amine (26 mg, 0.19 mmol) in IPA (0.6 mL), and then PTSA (30 mg, 0.16 mmol) was added. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain compound 64 (22 mg, 0.053 mmol, 33%) as a solid.

[0482] LC / MS (ESI) m / z 413.5 [M+H].

[0483] 1H NMR (300MHz, DMSO-d6) δ12.79 (s, 1H), 11.28 (s, 1H), 9.56 (s, 1H), 8.78-8.68 (m, 1H), 8.25 (s, 1H), 8.03 (bs, 1 H), 7.94 (bs, 1H), 7.66-7.48 (m, 3H), 3.32 (dd, J=9.0Hz, 1H), 7.18 (t, J=9.0Hz, 1H), 1.82 (s, 3H), 1.78 (s, 3H).

[0484] Compound 65: (2-((2-((1H-Indol-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0485] [Reaction 65]

[0486]

[0487] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol) was added to a solution of 1H-indol-5-amine (25 mg, 0.19 mmol) in IPA (0.6 mL), followed by PTSA (30 mg, 0.16 mmol). The reaction mixture was heated overnight at 80 °C. The crude mixture was purified by silica gel column chromatography using EA:MeOH (9.5 / 0.5) to obtain compound 65 (15 mg, 0.036 mmol, 23%) as a gray solid.

[0488] LC / MS (ESI) m / z 412.6 [M+H]+.

[0489] 1H NMR (300MHz, DMSO-d6) δ11.12 (s, 1H), 10.96 (s, 1H), 9.20 (s, 1H), 8.64 (bs, 1H), 8.15 (s, 1H), 7.86 (s, 1H), 7.57 (dd, J=1 5, 9.0Hz, 1H), 7.38 (t, J=9.0Hz, 1H), 7.33-7.26 (m, 2H), 7.24-7.10 (m, 2H), 6.35-6.31 (m, 1H), 1.80 (s, 3H), 1.76 (s, 3H).

[0490] Compound 66: (2-((2-((1H-Indazol-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0491] [Reaction 66]

[0492]

[0493] To a solution of 1H-indazole-5-amine (28 mg, 0.17 mmol) in IPA (0.6 mL) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (46 mg, 0.19 mmol). The reaction mixture was heated overnight at 80 °C. TLC showed the formation of new spots, the reaction was quenched with sodium bicarbonate, and extracted with DCM (20 ml × 2). The organic layer was dried over sodium sulfate, and the solvent was distilled off under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as a solvent mixture, and purification was performed by MPLC to obtain flocculent compound 66 (20 mg, 0.048 mmol, 30%).

[0494] LCMS: 413.2 [M+H]+.

[0495] 1H NMR (400MHz, DMSO-d6) δ12.91 (s, 1H), 11.09 (s, 1H), 9.39 (s, 1H), 8.56 (s, 1H), 8.18 (d, J=2.6Hz, 1H), 8.08 ( s, 1H), 7.93 (s, 1H), 7.68-7.53 (m, 1H), 7.51-7.40 (m, 3H), 7.19 (t, J=7.2Hz, 1H), 1.79 (s, 3H), 1.76 (s, 3H).

[0496] Compound 67: (2-((2-((3-Bromo-1H-indazol-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0497] [Reaction 67]

[0498]

[0499] 1) Synthesis of 3-bromo-1H-indazol-5-amine

[0500] Pd / C (10 mg, 10 mol%) was added to a solution of 3-bromo-5-nitro-1H-indazole (100 mg, 0.413 mmol) in 10 ml of MeOH and stirred overnight on a parr shaker. TLC showed that the reaction was complete, the catalyst was filtered and the solvent was evaporated to obtain compound 20-052 (77 mg, 0.363 mmol, 88%) as a purple solid.

[0501] 1H NMR (400MHz, DMSO-d6) δ 13.33 (s, 1H), 9.85 (s, 2H), 8.19 (s, 1H), 7.78 (s, 1H), 7.68 (d, J=8.9Hz, 1H), 7.31 (d, J=9.1Hz, 1H).

[0502] 2) 2-((2-((3-bromo-1H-indazol-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0503] To a solution of compound 20-052 (36.0 mg, 0.17 mmol) in IPA (0.6 mL) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (46 mg, 0.19 mmol). The reaction mixture was heated overnight at 80 ° C. TLC showed the formation of new spots, the reaction was quenched with sodium bicarbonate and extracted with DCM (20 ml × 2), the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as the solvent mixture and purified by MPLC to obtain flocculent compound 67 (25 mg, 0.050 mmol, 31%).

[0504] LCMS: 492.2 [M+H]+.

[0505] 1H NMR (400MHz, DMSO-d6) δ12.92 (s, 1H), 11.08 (s, 1H), 9.40 (s, 1H), 8.57 (s, 1H), 8.19 (s, 1H), 8.08 (s, 1H), 7.93 (s, 1H), 7.60 (dd, J=14.0, 7.8Hz, 1H), 7.45 (d, J=6.7Hz, 3H), 7.20 (t, J=7.8Hz, 1H), 1.79 (s, 3H), 1.76 (s, 3H).

[0506] Compound 68: (2-((2-((1H-Indol-4-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0507] [Reaction 68]

[0508]

[0509] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (114 mg, 0.360 mmol) to a 5 mL vial, 1H-indol-4-amine (50.0 mg, 0.378 mmol), PTSA (103 mg, 0.541 mmol), and IPA (1 ml) were added. The reaction mixture was heated at 95 ° C for 15 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (50 ml × 2) and water. The organic layer was dried with sodium sulfate and the solvent was distilled under vacuum. The solid was crushed and purified to obtain compound 68 (60.5 mg, 0.147 mmol, 41%) as a gray solid.

[0510] LC / MS: 412.30 [M+H]+.

[0511] 1H NMR (300MHz, CDCl3) δ10.92 (s, 1H), 8.63 (dd, J=8.6, 4.5Hz, 1H), 8.25 (s, br, 1H), 7.81 (dd, J=5.2, 3.4Hz, 1H), 7.42 (t, J=7.8Hz, 1H), 7.29 (s, 1H), 7.24-7.13 (m, 5H), 7.09 (t, J=7.5Hz, 1H), 6.58 (t, J=2.8Hz, 1H), 1.88 (s, 3H), 1.84 (s, 3H).

[0512] Compound 69: (2-((5-Chloro-2-((2-methyl-1H-indol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0513] [Reaction 69]

[0514]

[0515] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (103 mg, 0.326 mmol) to a 5 mL vial, 2-Methyl-1H-indol-5-amine (50.0 mg, 0.342 mmol), PTSA (93 mg, 0.541 mmol), and IPA (1 ml) were added. The reaction mixture was heated at 95 ° C for 15 hours. The reaction was quenched with sodium bicarbonate, extracted with DCM (50 ml × 2) and water, and the organic layer was dried with sodium sulfate. The solvent was distilled off under vacuum. The mixture was purified by MPLC using 3% to 5% (gradient) MeOH in MC to obtain compound 69 (34.2 mg, 0.147 mmol, 25%) as a white solid.

[0516] 1H NMR (400MHz, CDCl3) δ10.88 (s, 1H), 8.68 (s, 1H), 8.07 (s, 1H), 7.87 (s, 1H), 7.66 (d, J=60.2Hz, 1H), 7.32 (d, J =25.7Hz, 1H), 7.24-6.96 (m, 4H), 6.91 (d, J = 12.4Hz, 1H), 6.16 (s, 1H), 3.49 (s, 3H), 1.84 (s, 3H), 1.82 (s, 3H).

[0517] Compound 70: 7-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4-methyl-1H-indole-3-carbonitrile

[0518] [Reaction 70]

[0519]

[0520] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (100 mg, 0.316 mmol) to a 5 mL vial, 7-amino-4-methyl-1H-indole-3-carbonitrile (43.3 mg, 0.253 mmol), PTSA (96.3 mg, 0.506 mmol), and IPA (1 ml) were added. The reaction mixture was heated at 100 ° C for 6 hours. The reaction was quenched with sodium bicarbonate, extracted with DCM (50 ml × 2) and water, the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. The mixture was purified by MPLC using 5% MeOH in MC to obtain compound 70 (46.1 mg, 0.102 mmol, 32%) as a white solid.

[0521] 1H NMR (400MHz, DMSO) δ11.96 (s, br, 1H), 11.21 (s, 1H), 9.18 (s, 1H), 8.12 (d, J = 16.6Hz, 2H), 8.02 (s, 1H), 7.51 (d, J =10.7Hz, 1H), 7.24 (d, J = 7.6Hz, 1H), 7.05 (s, 2H), 6.91 (d, J = 7.7Hz, 1H), 2.66 (s, 3H), 1.77 (s, 3H), 1.73 (s, 3H).

[0522] Compound 71: (2-((2-((1H-Indol-7-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0523] [Reaction 71]

[0524]

[0525] 1) Synthesis of Compound 20-019

[0526] 50 ml of RB was filled with methanol. 7-nitroindole (350 mg, 2.16 mmol) and 10% Pd / C (35 mg) were added to the solution. After 15 hours, Pd / C was removed using a syringe filter. The filtrate was concentrated using a rotary evaporator to obtain compound 20-019 (302 mg, 2.28 mmol, 96%) as a pale purple solid.

[0527] 1H NMR (400MHz, CDCl3) δ 8.06 (s, 1H), 7.22 -7.15 (m, 1H), 7.11 (s, 1H), 6.96 (td, J=7.9, 2.5Hz, 1H), 6.58 (dd, J=7.5, 2.6Hz, 1H), 6.52 (d, J=3.2Hz, 1H).

[0528] 2)(2-((2-((1H-indol-7-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0529] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (100 mg, 0.316 mmol) to a 5 mL vial, compound 20-019 (44.2 mg, 0.332 mmol), PTSA (96.3 mg, 0.506 mmol), and IPA (1 ml) were added. The reaction mixture was heated at 90 ° C for 5 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (50 ml × 2) and water. The organic layer was dried with sodium sulfate and the solvent was distilled under vacuum. The mixture was purified by MPLC using 4% to 8% MeOH in MC (gradient) to obtain compound 71 (85.8 mg, 0.208 mmol, 66%) as a white + light pink solid.

[0530] 1H NMR (400MHz, DMSO) δ11.18 (s, 1H), 10.93 (s, 1H), 9.11 (s, 1H), 8.20 (s, br, 1H), 8.17 (s, 1H), 7.50 (ddd, J=14.0, 7.7, 1.7Hz, 1H), 7.33 (d, J=7.7H z, 2H), 7.28 (t, J=2.8Hz, 1H), 7.13 (s, 1H), 7.05 (d, J=7.3Hz, 1H), 6.94 (t, J=7.7Hz, 1H), 6.46 (dd, J=3.1, 1.9Hz, 1H), 1.75 (s, 3H), 1.73 (s, 3H).

[0531] Compound 72: 1-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)isoindolin-2-yl)-2,2,2-trifluoroethan-1-one

[0532] [Reaction 72]

[0533]

[0534] After adding 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50.0mg, 0.316mmol) to a 5mL vial, compound 17-122 (38.2mg, 0.166mmol), PTSA (45.1mg, 0.237mmol), IPA (0.5ml) were added. The reaction mixture was heated at 100°C for 6 hours. The reaction was quenched with sodium bicarbonate and extracted with DCM (50ml×2) and water, the organic layer was dried with sodium sulfate, and the solvent was distilled under vacuum. The mixture was purified by MPLC using 4% to 7% MeOH in MC (gradient) to obtain compound 72 (47.8mg, 0.0938mmol, 59%) as a white solid.

[0535] LCMS: 510.2 [M+H]+.

[0536] 1H NMR (300MHz, CDCl3) δ10.94 (d, J=6.8Hz, 1H), 8.52 (dt, J=9.5, 5.2Hz, 1H), 8.12 (d, J=1.5Hz, 1H), 7.77 (d, J=4.8Hz, 1H), 7.48 (t, J=8.1Hz, 1H), 7.38-7.27 (m, 2H), 7.25 -7.12 (m, 2H), 7.02 (d, J=3.6Hz, 1H), 4.99 (d, J=7.8Hz, 2H), 4.87 (d, J=8.4Hz, 2H), 1.87 (s, 3H), 1.83 (s, 3H).

[0537] Compound 73: (2-((5-Chloro-2-(isoindolin-5-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0538] [Reaction 73]

[0539]

[0540] LiOH·H2O (4.0 mg, 0.0953 mmol) was added to a solution of compound 20-030 (20.0 mg, 0.0392 mmol) in THF / MeOH / water (2:1:0.5) (1 ml) at room temperature. After 12 hours, the solvent was concentrated using a rotary evaporator, and an acid / base operation was performed using 1N HCl and NaOH to obtain compound 73 (10.0 mg, 0.0105 mmol, 96%) as a white solid.

[0541] 1H NMR (400MHz, CDCl3) δ10.92 (s, 1H), 8.61 (dt, J=8.3, 3.8Hz, 1H), 8.12 (d, J=3.3Hz, 1H), 7.61 (s, 1H), 7.51 (d, J= 8.5Hz, 1H), 7.36-7.30 (m, 1H), 7.25-7.09 (m, 2H), 7.02 (s, 1H), 4.24 (d, J=3.3Hz, 4H), 1.88 (s, 3H), 1.85 (s, 3H).

[0542] Compound 74: (2-((5-Chloro-2-(pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0543] [Reaction 74]

[0544]

[0545] To a solution of pyrrolo[2,1-f][1,2,4]triazin-4-amine (26 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol), followed by Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (2.8 mg, 0.0048 mmol), and cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160° C. for 40 minutes using a microwave. The reaction mass was filtered through celite bed and washed with EA, and the residue was purified by MPLC using 5% MeOH:MC as solvent mixture to obtain compound 74 (26.0 mg, 0.0628 mmol 40%) as a white solid.

[0546] 1H NMR (400MHz, chloroform-d) δ11.49 (s, 1H), 9.31 (dd, J=8.6, 4.6Hz, 1H), 8.27 (s, 2H), 7.81 (s, 1H), 7.72 (t, J=2.0Hz, 1H), 7.60 (t, J= 7.9Hz, 1H), 7.45 (d, J=10.8Hz, 1H), 7.16 (t, J=7.2Hz, 1H), 6.86-6.82 (m, 1H), 6.81-6.77 (m, 1H), 1.87 (s, 3H), 1.84 (s, 3H).

[0547] Compound 75: (2-((5-Chloro-2-((2-(trifluoromethyl)-1H-benzo[d]imidazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl phosphine oxide

[0548] [Reaction 75]

[0549]

[0550] 2-(Trifluoromethyl)-1H-benzimidazol-5-amine (32 mg, 0.19 mmol) solution in dioxane (0.6 ml) was added with 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), and then Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (2.8 mg, 0.0048 mmol), and cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 ° C for 40 minutes using microwaves. The reaction mass was filtered through a celite bed and washed with EA, and the solvent was evaporated under vacuum. The residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain a brown solid compound 75 (31.0 mg, 0.0645 mmol, 40%).

[0551] LCMS: 381.2 [M+H]+.

[0552] 1H NMR (500MHz, DMSO-d6) δ13.70 (s, 1H), 11.29 (s, 1H), 9.60 (s, 1H), 8.71 (s, 1H), 8.24 (s, 1H), 8.12 (s, 1H) , 7.67 (s, 1H), 7.63-7.55 (m, 2H), 7.49 (t, J=7.8Hz, 1H), 7.17 (t, J=7.5Hz, 1H), 1.81 (s, 3H), 1.78 (s, 3H).

[0553] Compound 76: (2-((5-Chloro-2-((2-mercapto-1H-benzo[d]imidazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0554] [Reaction 76]

[0555]

[0556] To a solution of 5-amino-1H-benzo[d]imidazole-2-thiol (26 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) (2.8 mg, 0.0048 mmol), cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 ° C for 40 minutes using microwaves. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, 5% MeOH:MC was used as a solvent mixture for the residue, and it was purified by MPLC to obtain compound 76 (16.0 mg, 0.0359 mmol 22%) as a yellow solid.

[0557] LCMS: 445.1 [M+H]+.

[0558] 1H NMR (500MHz, DMSO-d6) δ12.54 (s, 1H), 11.82 (s, 1H), 8.40 (s, 1H), 7.61 (dd, J=8.5, 4.3Hz, 1H), 7.45 (ddd, J=14.1, 7.7, 1.6Hz, 1H), 7.39 (d, J=8 .6Hz, 1H), 6.90-6.84 (m, 1H), 6.65 (dd, J=8.6, 2.1Hz, 1H), 6.63 (d, J=2.0Hz, 1H), 6.09 (t, J=7.8Hz, 1H), 5.15 (s, 2H), 1.76 (s, 3H), 1.74 (s, 3H).

[0559] Compound 77: (2-((5-Chloro-2-(imidazo[1,2-a]pyridin-8-ylamino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0560] [Reaction 77]

[0561]

[0562] To a solution of imidazo[1,2-a]pyridine-8-amine (26.4 mg, 0.19 mmol) in dioxane (0.6 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50 mg, 0.16 mmol), followed by the addition of Pd(OAc)2 (0.71 mg, 0.0032 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (2.8 mg, 0.0048 mmol), and cesium carbonate (104 mg, 0.32 mmol). The reaction mixture was heated at 160 ° C for 40 minutes using a microwave. The reaction mass was filtered through a celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 5% MeOH:MC as a solvent mixture to obtain compound 77 (16.0 mg, 0.0359 mmol, 22%) as a yellow solid.

[0563] LCMS: 413.1 [M+H]+.

[0564] 1H NMR (500MHz, DMSO-d6) δ12.54 (s, 1H), 11.82 (s, 1H), 8.40 (s, 1H), 7.61 (dd, J=8.5, 4.3Hz, 1H), 7.45 (ddd, J=14.1, 7.7, 1.6Hz, 1H), 7.39 (d, J=8 .6Hz, 1H), 6.90-6.84 (m, 1H), 6.65 (dd, J=8.6, 2.1Hz, 1H), 6.63 (d, J=2.0Hz, 1H), 6.09 (t, J=7.8Hz, 1H), 5.15 (s, 2H), 1.76 (s, 3H), 1.74 (s, 3H).

[0565] Compound 78: (2-((5-Chloro-2-((1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0566] [Reaction 78]

[0567]

[0568] 1-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine (24.6 mg, 0.166 mmol) was added to a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50.0 mg, 0.158 mmol) in IPA (1 ml), and then PTSA (54.2 mg, 0.285 mmol) was added. The reaction mixture was heated at 90°C for 3 hours. The reaction mixture was filtered, the solid was washed with MC, and then alkalized with sodium bicarbonate to obtain compound 78 (7.12 mg, 0.0166 mmol, 10%) as a white solid.

[0569] LC / MS: 426.38 [M+H+].

[0570] 1H NMR (400MHz, CDCl3) δ10.99 (s, 1H), 8.53-8.49 (m, 1H), 8.49 (s, 1H), 8.12 (s, 1H), 7.92 (s, 1H), 7.37 (t, J=7.9 Hz, 1H), 7.32-7.27 (m, 1H), 7.17-7.09 (m, 1H), 7.00 (d, J=1.6Hz, 1H), 4.17 (s, 3H), 1.86 (s, 3H), 1.83 (s, 3H).

[0571] Compound 79: (2-((2-((1H-pyrrolo[2,3-b]pyridin-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0572] [Reaction 79]

[0573]

[0574] To a solution of 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (50.0 mg, 0.158 mmol) in IPA (1 ml) was added 1H-pyrrolo[2,3-b]pyridine-5-amine (23.2 mg, 0.174 mmol), followed by PTSA (45.1 mg, 0.316 mmol). The reaction mixture was heated at 90°C for 14 hours. The reaction mixture was filtered, the solid was washed with MC, and then alkalized with sodium bicarbonate. The reaction mixture was purified by silica gel column chromatography using 5% MeOH in DCM to obtain compound 79 (43.8 mg, 0.106 mmol, 67%) as a white solid.

[0575] LC / MS: 411.82 [M+H+].

[0576] 1H NMR (400MHz, DMSO) δ11.51 (s, 1H), 11.13 (s, 1H), 9.34 (s, 1H), 8.53 (s, 1H), 8.29 (d, J=2.4Hz, 1H), 8.22 (d, J=2.4Hz, 1H), 8.17 (s, 1H), 7.57 (ddd, J=13. 9, 7.7, 1.6Hz, 1H), 7.46-7.41 (m, 1H), 7.34 (d, J=9.5Hz, 1H), 7.15 (tdd, J=7 .5, 2.2, 1.1Hz, 1H), 6.36 (dd, J=3.4, 1.9Hz, 1H), 1.79 (s, 3H), 1.76 (s, 3H).

[0577] Compound 80: (2-((5-Chloro-2-((1-isopropyl-1H-pyrazolo[4,3-c]pyridin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0578] [Reaction 80]

[0579]

[0580] 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (25.0 mg, 0.0799 mmol) was added to a solution of 1-isopropyl-1H-pyrazolo[4,3-c]pyridin-6-amine (15.1 mg, 0.086 mmol) in dioxane (2 ml), followed by Pd(OAc)2 (1.77 mg, 0.00799 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (4.56 mg, 0.00790 mmol), and cesium carbonate (52.0 mg, 0.160 mmol). The reaction mixture was heated at 160°C for 40 minutes using a microwave. The reaction mass was filtered through celite bed and washed with EA, the solvent was evaporated under vacuum, and the residue was purified by MPLC using 10% MeOH:MC as solvent mixture to obtain Compound 80 (16.0 mg, 0.0350 mmol, 43%) as a yellow solid.

[0581] LCMS: 456.2 [M+H]+.

[0582] 1H NMR (500MHz, chloroform-d) δ11.01 (s, 1H), 8.78 (d, J=1.1Hz, 1H), 8.72-8.62 (m, 1H), 8.34 (d, J=1.1Hz, 1H), 8.30 (s, 1H), 8.28 (s, 1H), 8.04 (s , 1H), 7.56-7.50 (m, 1H), 7.40-7.31 (m, 1H), 7.21-7.14 (m, 1H), 4.66 (h, J=6.5Hz, 1H), 1.89 (d, J=13.2Hz, 6H), 1.55 (d, J=6.6Hz, 6H).

[0583] Compound 81: (2-((2-((3-Bromo-1H-pyrazolo[3,4-b]pyridin-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethyl phosphine oxide)

[0584] [Reaction 81]

[0585]

[0586] 1) Synthesis of 3-bromo-1H-indazol-5-amine

[0587] Pd / C (100 mg, 10 mol%) was added to a solution of 3-bromo-5-nitro-1H-indazole (1.0 g, 4.13 mmol) in 10 ml of MeOH and stirred overnight on a parr shaker. TLC showed that the reaction was complete, the catalyst was filtered and the solvent was evaporated to give 3-bromo-1H-indazole-5-amine (691 mg, 3.25 mmol, 78%) as a slightly impure purple solid.

[0588] 1H NMR (400MHz, DMSO-d6) δ 12.91 (s, 1H), 7.27 (d, J=8.8Hz, 1H), 6.86 (dd, J=8.9, 2.1Hz, 1H), 6.54 (d, J=1.9Hz, 1H), 5.02 (s, 2H).

[0589] 2)(2-((2-((3-bromo-1H-pyrazolo[3,4-b]pyridin-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0590] To a solution of 3-bromo-1H-indazole-5-amine (890 mg, 2.82 mmol) in IPA (10 ml) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidine-4-amine (890 mg, 2.82 mmol), followed by the addition of PTSA (804 mg, 4.23 mmol). The reaction mixture was heated overnight at 90 °C. TLC showed the formation of new spots, the reaction was quenched with sodium bicarbonate, extracted with DCM (20 ml × 2), the organic layer was filtered over sodium sulfate, and the solvent was distilled under vacuum. The crude mixture was purified by MPLC using 5% MeOH:DCM as a solvent mixture to obtain flocculent compound 81 (350 mg, 0.713 mmol, 25%).

[0591] LCMS: 493.2 [M+H]+.

[0592] 1H NMR (400MHz, DMSO-d6) δ12.92 (s, 1H), 11.09 (s, 1H), 9.40 (s, 1H), 8.57 (s, 1H), 8.19 (s, 1H), 8.09 (s, 1H), 7.9 3 (s, 1H), 7.60 (ddd, J=13.8, 7.7, 1.6Hz, 1H), 7.52-7.41 (m, 3H), 7.24-7.15 (m, 1H), 1.80 (s, 3H), 1.76 (s, 3H).

[0593] Compound 82: (2-((2-((1H-pyrazolo[3,4-b]pyridin-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0594] [Reaction 82]

[0595]

[0596] To a solution of 3-bromo-1H-pyrazolo[3,4-b]pyridin-5-amine (22.8 mg, 0.17 mmol) in IPA (0.6 mL) was added 2,5-dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine (50 mg, 0.16 mmol), followed by the addition of PTSA (46 mg, 0.19 mmol). The reaction mixture was heated overnight at 90°C. TLC showed the formation of a new spot, the solid was filtered, dissolved in water, washed with sodium bicarbonate (pH 7-8), washed with 10 ml of MC, extracted with DCM (20 ml x 2), and the organic layer was dried. Sodium sulfate and the solvent were distilled in vacuo to obtain compound 82 (21 mg, 0.050 mmol, 31%) as a fluffy solid.

[0597] LCMS: 414.3 [M+H]+.

[0598] 1H NMR (400MHz, DMSO-d6) δ13.52 (s, 1H), 11.11 (s, 1H), 9.58 (s, 1H), 8.62 (d, J=2.4Hz, 1H), 8.47 (s, 2H) , 8.22 (s, 1H), 8.03 (d, J = 1.4Hz, 1H), 7.61 (ddd, J = 13.9, 7.7, 1.6Hz, 1H), 7.43 (t, J = 7.9Hz, 1H), 7.25 -7.17 (m, 1H), 1.78 (d, J=13.5Hz, 6H).

[0599] Compound 83: (2-((5-Chloro-2-((3-(2-fluoropyridin-3-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl phosphine oxide

[0600] [Reaction 83]

[0601]

[0602] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) in dioxane / water (2 ml) was added 2-fluoropyridine-3-boronic acid (17.3 mg, 0.122 mmol), followed by the addition of bistriphenylphosphoin palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110° C. for 10 minutes using a microwave. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The unpurified mixture was purified by MPLC using 5% MeOH:DCM as a solvent mixture to obtain compound 83 (7.0 mg, 0.014 mmol, 13%) as a white solid.

[0603] LCMS: 508 [M+H]+.

[0604] 1H NMR (400MHz, DMSO-d6) δ13.45 (s, 1H), 11.15 (s, 1H), 9.47 (s, 1H), 8.51 (s, 1H), 8.33-8.25 (m, 2H), 8.19 (s, 1H), 8.09 (d, J=2.6Hz, 1H ), 7.67 (dd, J=9.4, 1.8Hz, 1H), 7.56 (d, J=9.0Hz, 1H), 7.53-7.42 (m, 2H), 7.11 (s, 1H), 7.01-6.88 (m, 1H), 1.81 (s, 3H), 1.77 (s, 3H).

[0605] Compound 84: (2-((2-((3-(1H-pyrazol-4-yl)-1H-indazol-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethyl phosphine oxide

[0606] [Reaction 84]

[0607]

[0608] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 mL) was added (1H-pyrazol-4-yl)boronic acid (20.2 mg, 0.181 mmol), bistriphenylphosphine palladium dichloride (20.2 mg, 0.181 mmol), and then bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110° C. for 10 minutes using a microwave. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The unpurified mixture was purified by MPLC using 5% MeOH:DCM as a solvent mixture to obtain compound 84 (9.0 mg, 0.018 mmol, 18%) as a white solid.

[0609] LCMS: 479.1 [M+H]+.

[0610] Compound 85: tert-butyl tert-butyl 4-(5-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate

[0611] [Reaction 85]

[0612]

[0613] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 ml), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (20.2 mg, 0.181 mmol) was added, followed by the addition of bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110 ° C for 10 minutes using a microwave. TLC showed the formation of new spots, the solid was filtered and the solvent was evaporated under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as a solvent mixture and purified by MPLC to obtain compound 85 (19.0 mg, 0.0319 mmol, 31%) as a white solid.

[0614] LCMS: 594.1 [M+H]+.

[0615] 1H NMR (400MHz, DMSO-d6) δ12.89 (s, 1H), 11.21 (s, 1H), 9.35 (s, 1H), 8.59 (s, 1H), 8.27-8.14 (m, 2H), 7.62-7.49 (m, 2H), 7.46 (d, J=8.9Hz, 1H), 7.25(s, 1H), 7.08(t, J=7.5Hz, 1H), 6.29(s, 1H), 3.91(s, 2H), 3.61-3 .48(m, 2H), 2.71-2.60(m, 2H), 1.81(s, 3H), 1.78(s, 3H), 1.43(s, 9H).

[0616] Compound 86: 5-Fluoro-N 2 -(1H-indazol-5-yl)-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 -(1H-indazol-5-yl)-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0617] [Reaction 86]

[0618]

[0619] To a solution of compound 20-105 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added 5-amino-1H-indazole (5-Amino-1H-indazole) (22.6 mg, 0.170 mmol), and then PTSA (46.2 mg, 0.243 mmol) was added. The reaction mixture was heated at 90° C. for 15 hours. The reaction mixture was alkalized with sodium bicarbonate and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 80% EA in hexane (hex) for 20 minutes and 5% MeOH in MC for 20 minutes to obtain compound 86 (9.25 mg, 0.0228 mmol, 14%) as a white solid.

[0620] LC / MS: 406.21 [M+H+].

[0621] 1H NMR (400MHz, DMSO) δ12.83 (s, 1H), 9.00 (s, 1H), 8.248.18 (m, 1H), 7.95 (s, 1 H), 7.89 (d, J=3.8Hz, 1H), 7.50 (dd, J=9.0, 2.0Hz, 1H), 7.41 (d, J=8.9Hz, 1H ), 7.34 (d, J = 7.7Hz, 1H), 4.084.00 (m, 1H), 3.63 (d, J = 12.2Hz, 2H), 2.92 (s, 3H), 2.892.80 (m, 2H), 2.02 (d, J=12.7Hz, 2H), 1.65 (qd, J=12.0, 4.1Hz, 2H).

[0622] Compound 87: 5-Fluoro-N 2 -(1H-indazol-6-yl)-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 -(1H-indazol-6-yl)-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0623] [Reaction 87]

[0624]

[0625] To a solution of compound 20-105 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added 5-amino-1H-indazole (22.6 mg, 0.170 mmol), followed by PTSA (46.2 mg, 0.243 mmol). The reaction mixture was heated at 90°C for 7 hours. The solid was filtered, basified with sodium bicarbonate, and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 80% EA in Hex to obtain compound 87 (9.25 mg, 0.0228 mmol, 14%) as a white solid.

[0626] 1H NMR (500MHz, DMSO) δ12.73 (s, 1H), 9.23 (s, 1H), 8.19 (s, 1H), 7.95 (d, J=3.6 Hz, 1H), 7.89 (s, 1H), 7.56 (d, J=8.7Hz, 1H), 7.41 (d, J=7.7Hz, 1H), 7.25 (dd, J=8.8, 1.8Hz, 1H), 4.10 (dt, J=7.6, 3.9Hz, 1H), 3.62 (d, J=12.1Hz, 2H), 2.9 3 (s, 3H), 2.88 (d, J=10.3Hz, 2H), 2.02 (d, J=12.4Hz, 2H), 1.73-1.61 (m, 2H).

[0627] Compound 88: N 2 -(3-Bromo-1H-indazol-5-yl)-5-fluoro-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (N 2 -(3-Bromo-1H-indazol-5-yl)-5-fluoro-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0628] [Reaction 88]

[0629]

[0630] To a solution of compound 20-127 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added 3-bromo-1H-indazole-5-amine (36.1 mg, 0.170 mmol), followed by PTSA (46.2 mg, 0.243 mmol). The reaction mixture was heated at 90° C. for 16 hours. The solid was filtered, basified with sodium bicarbonate, and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 80% EA in Hex to obtain compound 88 (61.1 mg, 0.126 mmol, 78%) as a white solid.

[0631] LC / MS: 486.21 [M+H+].

[0632] 1H NMR (400MHz, DMSO) δ13.21 (s, 1H), 9.21 (s, 1H), 8.16 (d, J=1.9Hz, 1H), 7.93 (d, J=3.8Hz, 1H), 7.54 (dd, J=9.1, 2.0Hz, 1H), 7.45 (d, J=9.0Hz, 1H ), 7.39 (d, J = 7.8Hz, 1H), 4.21-4.07 (m, 1H), 3.60 (d, J = 12.2Hz, 2H), 2.9 0 (s, 3H), 2.90-2.83 (m, 2H), 2.00 (d, J=14.4Hz, 2H), 1.74-1.59 (q, 2H).

[0633] Compound 89: 5-Fluoro-N 2 -(1H-Indol-5-yl)-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 -(1H-indol-5-yl)-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0634] [Reaction 89]

[0635]

[0636] To a solution of compound 20-127 (50.0 mg, 0.162 mmol) in IPA (1 ml) was added 5-amino-indole (22.5 mg, 0.170 mmol), followed by PTSA (46.2 mg, 0.243 mmol). The reaction mixture was heated at 90°C for 16 hours. The solid was filtered, basified with sodium bicarbonate, and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 80% EA in Hex to obtain compound 89 (29.0 mg, 0.0717 mmol, 45%) as a white solid.

[0637] LC / MS: 405.27 [M+H+].

[0638] 1H NMR (400MHz, DMSO) δ10.84 (s, 1H), 8.74 (s, 1H), 7.95 (s, 1H), 7.85 (d, J = 3.8Hz, 1H), 7.25 (d, J = 1.9Hz, 3H), 6.31 (t, J = 2.5Hz, 1H), 4 .03 (q, J=7.0Hz, 1H), 3.63 (d, J=11.9Hz, 2H), 2.91 (s, 3H), 2.88-2.78 (m, 2H), 2.01 (d, J=17.1Hz, 2H), 1.63 (q, J=11.6, 10.9Hz, 2H).

[0639] Compound 90: 5-Fluoro-N 2 -(2-methyl-1H-indol-5-yl)-N 4 -(1-(Methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine (5-Fluoro-N 2 -(2-methyl-1H-indol-5-yl)-N 4 -(1-(methylsulfonyl)piperidin-4-yl)pyrimidine-2,4-diamine)

[0640] [Reaction 90]

[0641]

[0642] To a solution of compound 20-127 (50.0 mg, 0.162 mmol) dissolved in IPA (1 ml) was added 5-amino-2-methylindole (24.9 mg, 0.170 mmol), followed by PTSA (46.2 mg, 0.243 mmol). The reaction mixture was heated at 90° C. for 16 hours. The reaction mixture was alkalized with sodium bicarbonate and extracted with DCM. The reaction mixture was purified by silica gel column chromatography using 80% EA in Hex to obtain compound 90 (25.4 mg, 0.0607 mmol, 38%) as a white solid.

[0643] LC / MS: 419.37 [M+H+].

[0644] 1H NMR (400MHz, DMSO) δ10.64 (s, 1H), 8.67 (s, 1H), 7.81 (dd, J=15.8, 2.9Hz, 2H), 7.25 (d, J=7.7Hz, 1H), 7.21-6.99 (m, 2H), 6.00 (s, 1H) , 4.03 (d, J=7.5Hz, 1H), 3.63 (d, J=11.9Hz, 2H), 2.91 (s, 3H), 2.89-2.73 (m, 2H), 2.34 (s, 3H), 2.06-1.94 (m, 2H), 1.74-1.55 (m, 2H).

[0645] Compound 91: 2-((5-Chloro-2-((3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl phosphineoxide

[0646] [Reaction 91]

[0647]

[0648] At room temperature, 4N HCl / dioxane (0.0105 mL, 0.042 mmol) was added to a solution of compound 20-228 (1.0 g, 1.3 mol) in 0.25 ml of DCM, stirred for 2 hours, and the solvent was evaporated. The residue was dissolved in water, washed with DCM, alkalized with sodium bicarbonate, extracted with DCM (15 ml × 2), and the organic layer was dried over sodium sulfate. The organic layer was evaporated under vacuum to obtain compound 91 (6.0 mg, 0.012 mmol, 75%) as a white solid.

[0649] LCMS: 494.6 [M+H]+.

[0650] 1H NMR (400MHz, DMSO-d6) δ12.80 (s, 1H), 11.23 (s, 1H), 9.33 (s, 1H), 8.62 (s, 1H), 8.18 (s, 1H), 8.15 (s, 1H), 7.64 -7.52 (m, 2H), 7.44 (d, J=8.9Hz, 1H), 7.31 (s, 1H), 7.11 (t, J=7.4Hz, 1H), 6 .36(s, 1H), 2.93(t, J=5.6Hz, 2H), 2.55(s, 2H), 1.80(s, 3H), 1.77(s, 3H).

[0651] Compound 92: 5-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)furan-2-carbaldehyde

[0652] [Reaction 92]

[0653]

[0654] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 ml) was added (5-formylfuran-2-yl)boronic acid (25.3 mg, 0.181 mmol), followed by the addition of bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110° C. for 30 minutes using a microwave. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The unpurified mixture was purified by MPLC using 5% MeOH:DCM as a solvent mixture to obtain compound 92 (9.0 mg, 0.018 mmol, 18%) as a white solid.

[0655] LCMS: 507.2 [M+H]+.

[0656] 1H NMR (400MHz, DMSO-d6) δ13.59 (s, 1H), 11.27 (s, 1H), 9.57 (s, 1H), 9.50 (s, 1H), 8.61 (s, 1H), 8.51 (s, 1H), 8.23 ​​(s, 1H) , 7.66-7.55 (m, 3H), 7.50 (dd, J=14.5, 8.0Hz, 1H), 7.07 (d, J=3.7Hz, 2H), 6.99-6.90 (m, 1H), 1.81 (s, 3H), 1.77 (s, 3H).

[0657] Compound 93: (2-((5-Chloro-2-((3-(1-isopropyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide)

[0658] [Reaction 93]

[0659]

[0660] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 ml) was added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-isopropyl-1H-pyrazole (42.7 mg, 0.181 mmol), then bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110° C. using a microwave for 30 minutes. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The crude mixture was purified by MPLC using 5% MeOH:DCM as solvent mixture to afford compound 93 (16.0 mg, 0.0307 mmol, 30%) as a brown solid.

[0661] LCMS: 521.96 [M+H]+.

[0662] 1H NMR (500MHz, DMSO-d6) δ12.83 (s, 1H), 11.19 (s, 1H), 9.32 (s, 1H), 8.58 (d, J = 16.6Hz, 1H), 8.21 (s, 1H), 8.19 (s, 1H), 8.15 (s, 1H), 7 .89 (s, 1H), 7.84-7.67 (m, 1H), 7.61-7.41 (m, 4H), 6.99 (s, 2H), 4.58-4.47 (m, 1H), 1.78 (s, 3H), 1.76 (s, 3H), 1.42 (d, J=6.7Hz, 6H).

[0663] Compound 94: (2-((5-Chloro-2-((3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide)

[0664] [Reaction 94]

[0665]

[0666] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 ml) was added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-methyl-1H-pyrazole (42.7 mg, 0.181 mmol), followed by bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110° C. for 30 minutes using a microwave. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The crude mixture was purified by MPLC using 5% MeOH:DCM as solvent mixture to afford compound 94 (24.0 mg, 0.0486 mmol, 48%) as a white solid.

[0667] LCMS: 493.6 [M+H]+.

[0668] 1H NMR (400MHz, DMSO-d6) δ12.83 (s, 1H), 11.21 (s, 1H), 9.33 (s, 1H), 8.57 (s, 1H), 8.19 (s, 1H), 8.15 (s, 1H), 8.11 (s, 1H), 7.86(s, 1H), 7.84-7.65(m, 1H), 7.59-7.42(m, 3H), 7.13-6.92(m, 1H), 3.85(s, 3H), 1.80(s, 3H), 1.77(s, 3H).

[0669] Compound 95: (2-((5-Chloro-2-((3-(1-propyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide)

[0670] [Reaction 95]

[0671]

[0672] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 ml) was added 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (42.7 mg, 0.181 mmol), then bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110° C. for 30 minutes using a microwave. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The unpurified mixture was purified by MPLC using 5% MeOH:DCM as solvent mixture to obtain compound 95 (27.0 mg, 0.0518 mmol, 51%) as a white solid.

[0673] LCMS: 521.6 [M+H]+.

[0674] 1H NMR (400MHz, DMSO-d6) δ12.83 (s, 1H), 11.19 (s, 1H), 9.31 (s, 1H), 8.65-8.49 (m, 1H) , 8.19 (d, J=3.0Hz, 2H), 8.16-8.11 (m, 1H), 7.89 (s, 1H), 7.79 (td, J=7.9, 3.6Hz, 1H), 7.70 (ddd, J=13.6, 8.4, 1.3Hz, 1H), 7.56-7.48 (m, 2H), 7.46 (d, J=8.8Hz, 1H), 6.98 ( s, 1H), 4.08 (t, J=6.9Hz, 2H), 1.82-1.77 (m, 5H), 1.76 (s, 3H), 0.82 (t, J=7.4Hz, 3H).

[0675] Compound 96: (2-((5-Chloro-2-((3-phenyl-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0676] [Reaction 96]

[0677]

[0678] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 ml) was added phenylboronic acid (18.5 mg, 0.151 mmol), followed by the addition of bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110° C. for 30 minutes using a microwave. TLC showed the formation of new spots, the solid was filtered and the solvent was evaporated under vacuum. The crude mixture was purified by MPLC using 5% MeOH:DCM as a solvent mixture to obtain compound 96 (14.0 mg, 0.0286 mmol, 28%) as a white solid.

[0679] LCMS: 489.6 [M+H]+.

[0680] 1H NMR (400MHz, DMSO-d6) δ11.40 (s, 1H), 9.62 (s, 1H), 8.53 (s, 1H), 8.28-8.18 (m, 2H), 7.92 (dd, J=7.3, 1.6Hz, 2H), 7.62 (d d, J=8.9, 1.9Hz, 1H), 7.58-7.50 (m, 2H), 7.46 (t, J=7.6Hz, 2H), 7.40-7.34 (m, 1H), 7.03 (s, 2H), 1.79 (d, J=13.5Hz, 6H).

[0681] Compound 97: (2-((5-Chloro-2-((3-(3-nitrophenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethyloxide phosphine

[0682] [Reaction 97]

[0683]

[0684] To a solution of compound 20-214 (50.0 mg, 0.101 mmol) dissolved in dioxane / water (2 ml) was added bistriphenylphosphine palladium dichloride (14.1 mg, 0.0202 mmol) and sodium carbonate (32.1 mg, 0.303 mmol). The reaction mixture was heated at 110°C using a microwave for 30 minutes. TLC showed the formation of new spots, the solid was filtered and the solvent was evaporated under vacuum. The crude mixture was purified by MPLC using 5% MeOH:DCM as a solvent mixture to obtain compound 97 (16.0 mg, 0.0299 mmol, 29%) as a green solid.

[0685] LCMS: 534.6. [M+H]+.

[0686] 1H NMR (500MHz, DMSO-d6) δ13.44 (s, 1H), 11.26 (s, 1H), 9.57 (s, 1H), 8.58 (d, J = 39.6Hz, 3H), 8.34 (d, J = 7.8Hz, 1H), 8.23 ​​(s, 1H), 8.20-8.12 (m , 1H), 7.71 (t, J=8.0Hz, 1H), 7.64 (d, J=9.1Hz, 1H), 7.59 (d, J=8.9Hz, 1H), 7.53-7.41 (m, 1H), 7.24-6.73 (m, 2H), 1.81 (s, 3H), 1.78 (s, 3H).

[0687] Compound 98: (2-((5-Chloro-2-((3-(2-fluoropyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)amino)pyrimidine-4-yl)amino)phenyl)dimethylphosphine oxide)

[0688] [Reaction 98]

[0689]

[0690] To a solution of compound 20-289 (30.0 mg, 0.0610 mmol) dissolved in dioxane / water (2 ml) was added (2-fluoropyridin-3-yl)boronic acid (13.0 mg, 0.0915 mmol), followed by bistriphenylphosphine palladium dichloride (8.5 mg, 0.0122 mmol) and sodium carbonate (20.1 mg, 0.183 mmol). The reaction mixture was heated at 110° C. for 30 minutes using a microwave. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The crude mixture was purified by MPLC using 5% MeOH:DCM as a solvent mixture to obtain compound 98 (5.0 mg, 0.0098 mmol, 16%) as a white solid.

[0691] LCMS: 509.2 [M+H]+.

[0692] 1H NMR (400MHz, chloroform-d) δ10.90 (s, 1H), 8.79 (dd, J=12.6, 2.5Hz, 2H), 8.73-8.47 (m, 2H), 8.45-8.38 (m, 1H), 8.31 (dd, J=8.4, 4.3Hz, 1H), 8.27-8.22 (m , 1H), 8.20 (s, 1H), 7.38-7.32 (m, 1H), 7.15 (ddd, J=14.0, 7.7, 1.6Hz, 1H) , 6.98 (t, J=7.9Hz, 1H), 6.72 (t, J=7.3Hz, 1H), 1.93 (s, 3H), 1.90 (s, 3H).

[0693] Compound 99: 1-(4-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)-3,6-dihydropyridin-1(2H)-yl)ethan-1-one

[0694] [Reaction 99]

[0695]

[0696] At 0 ° C, acetic anhydride (6.21 mg, 0.0608 mmol) was added to a suspension of compound 20-353 (20.0 mg, 0.0405 mmol) in 1 mL of DCM, and TEA (12.8 mg, 0.121 mmol) was added to the reaction mixture and stirred for 2 hours. TLC showed that the starting material was consumed. The friction was quenched with 5 ml of water, and DCM (20 ml × 2) was used for extraction. The organic layer was dried with sodium sulfate and evaporated under vacuum to obtain compound 99 (7.00 mg, 0.013 mmol, 32%) as a white solid.

[0697] Nuclear magnetic resonance (NMR) showed that the product existed in the form of rotamers with a ratio of 3:2.

[0698] LCMS: 536.6[M+H]+, 558.6[M+Na]+.

[0699] 1H NMR (400MHz, chloroform-d) δ11.18-11.02 (m, 1H), 8.69-8.55 (m, 1H), 8.30 (s, 0.6H), 8.19 (s, 0.4H), 8.16-8.10 (m, 1 H), 7.46 (s, 1H), 7.46-7.28 (m, 1.6H), 7.28-7.13 (m, 2.4H), 7.10-6.97 (m, 1H), 6.42-6.35 (m, 0.4H), 6.28-6 .21 (m, 0.6H), 4.14-4.05 (m, 0.80H), 3.99 (s, 1.20H), 3.82 (t, J=5.6Hz, 0.8H), 3.67 (t, J=5.6Hz, 1.2H), 2.8 9-2.80 (m, 1.2H), 2.81-2.73 (m, 0.8H), 2.20 (s, 2.0H), 2.13 (s, 1H), 1.93 (s, 2H), 1.90 (s, 3H), 1.86 (s, 1H).

[0700] Compound 100: (2-((2-((3-(3-Aminophenyl)-1H-indazol-5-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0701] [Reaction 100]

[0702]

[0703] Pd / C (3.0 mg, 10 mol%) was added to a suspension of compound 20-004 (30.0 mg, 0.0561 mmol) in 5 ml of MeOH at room temperature. The resulting mixture was shaken in a parr reactor for 12 hours under a hydrogen atmosphere (50 psi). TLC showed that the reaction was complete, the catalyst was filtered through a diatomaceous earth bed and washed with MeOH, and the solvent was completely evaporated under vacuum. For the unpurified mixture, 15% MeOH:MC was used as a solvent mixture and purified by MPLC to obtain compound 100 (9.0 mg, 0.0178 mmol, 31%) as an off-white solid.

[0704] LCMS: 504.1 [M+H]+.

[0705] 1H NMR (500MHz, DMSO-d6) δ11.11-11.04 (m, 1H), 9.18-9.09 (m, 1H), 8.65-8.58 (m, 1H), 8.4 6-8.39 (m, 1H), 8.17-8.05 (m, 2H), 7.78 (d, J=8.9Hz, 1H), 7.66 (dd, J=9.0, 1.8Hz, 1H), 7. 35 (dd, J=14.2, 7.6Hz, 1H), 7.16 (d, J=7.6Hz, 1H), 7.08 (t, J=7.7Hz, 1H), 6.98-6.89 (m, 2H), 6.72 (s, 1H), 6.65 (dd, J=8.2, 2.6Hz, 1H), 5.97 (d, J=5.9Hz, 2H), 1.76-1.68 (m, 6H).

[0706] Compound 101: (2-((5-Chloro-2-((3-(5-(hydroxymethyl)furan-2-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide)

[0707] [Reaction 101]

[0708]

[0709] 1) 5-(5-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)furan-2-carbaldehyde

[0710] To a solution of compound 20-343 (200 mg, 0.406 mmol) in dioxane: water (5 ml) was added (5-formylfuran-2-yl)boronic acid (102 mg, 0.488 mmol), followed by bistriphenylphosphine palladium dichloride (57.0 mg, 0.0812 mmol) and sodium carbonate (129 mg, 1.21 mmol). The reaction mixture was heated at 110° C. for 4 hours. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The unpurified mixture was purified by MPLC using 5% MeOH:EA as a solvent mixture to obtain compound 20-351 (30.0 mg, 0.059 mmol, 14.5%) as an orange solid.

[0711] 1H NMR (400MHz, DMSO-d6) δ13.59 (s, 1H), 11.27 (s, 1H), 9.57 (s, 1H), 9.50 (s, 1H), 8.61 (s, 1H), 8.51 (s, 1H), 8.23 ​​(s, 1H) , 7.66-7.55 (m, 3H), 7.50 (dd, J=14.5, 8.0Hz, 1H), 7.07 (d, J=3.7Hz, 2H), 6.99-6.90 (m, 1H), 1.81 (s, 3H), 1.77 (s, 3H).

[0712] 2)(2-((5-chloro-2-((3-(5-(hydroxymethyl)furan-2-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide)

[0713] Sodium borohydride (1.67mg, 0.0355mmol) was added to a suspension of compound 20-351 (15.0mg, 0.0295mmol) in MeOH (1ml) at 0°C, and stirred for 20 minutes at 0°C. TLC showed that a new spot had formed, and the reaction was quenched with water and the solvent was completely evaporated. The residue was diluted with water and extracted with DCM (15ml×2), and the combined organic layer was dehydrated with sodium sulfate and the solvent was evaporated under vacuum. 10% MeOH:MC was used as a solvent mixture for the crude mixture, and purified by MPLC to obtain compound 101 (3.50mg, 0.00687mmol, 23%) as a white solid.

[0714] LCMS: 509 [M+H]+.

[0715] 1H NMR (500 MHz, chloroform-d) δ 11.07 (s, 1H), 8.67 (dd, J = 8.5, 4.4 Hz, 1H), 8.29 (d, J = 1.9 Hz, 1H), 8.14 (s, 1H), 7.54 (dd, J = 8.9, 2.0 Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.27 -7.21(m, 2H), 7.20-7.13(m, 1H), 7.01-6.96(m, 1H), 6.79(d, J=3.3Hz, 1H), 6. 40 (d, J=3.3Hz, 1H), 4.64 (s, 2H), 2.09-2.04 (m, 1H), 1.88 (s, 3H), 1.85 (s, 3H).

[0716] Compound 102: tert-Butyl 4-(5-((4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)piperidin-1-carboxylate

[0717] [Reaction 102]

[0718]

[0719] 1) tert-butyl4-(5-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate

[0720] To a solution of 20-343 (150 mg, 0.305 mmol) dissolved in dioxane / water (2 ml) was added tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (170 mg, 0.549 mmol), followed by bistriphenylphosphine palladium dichloride (42.8 mg, 0.061 mmol) and sodium carbonate (97.0 mg, 0.915 mmol). The reaction mixture was heated at 110°C for 4 hours using a microwave. TLC showed the formation of a new spot, the solid was filtered and the solvent was evaporated under vacuum. The unpurified mixture was purified using 5% MeOH:DCM as the solvent mixture to afford compound 20-346 (176 mg, 0.296 mmol, 72%) as an off-white solid.

[0721] LCMS: 594.1 [M+H]+.

[0722] 1H NMR (400MHz, DMSO-d6) δ12.89 (s, 1H), 11.21 (s, 1H), 9.35 (s, 1H), 8.59 (s, 1H), 8.27-8.14 (m, 2H), 7.62-7.49 (m, 2H), 7.46 (d, J=8.9Hz, 1H), 7.25(s, 1H), 7.08(t, J=7.5Hz, 1H), 6.29(s, 1H), 3.91(s, 2H), 3.61-3 .48(m, 2H), 2.71-2.60(m, 2H), 1.81(s, 3H), 1.78(s, 3H), 1.43(s, 9H).

[0723] 2) tert-butyl 4-(5-((4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)piperidine-1-carboxylate

[0724] Pt / O2 (7.5 mg, 15 mol%) was added to a suspension of compound 20-346 (50.0 mg, 0.0843 mmol) in 0.5 ml of DMF and EtOH (4.5 ml) at room temperature. The resulting mixture was shaken in a parr reactor for 36 hours under a hydrogen atmosphere (50 psi). TLC showed the formation of new spots, and the mixture was filtered through a celite bed and washed with EtOH. The solvent was completely evaporated under vacuum. For the unpurified mixture, 15% MeOH:MC was used as a solvent mixture and purified by MPLC to obtain compound 102 (7.0 mg, 0.0124 mmol, 14%) as a purple solid.

[0725] 1H NMR (500MHz, DMSO-d6) δ12.53 (s, 1H), 10.95 (s, 1H), 9.18 (s, 1H), 8.52 (s, 1H), 8.13-8.02(m, 2H), 7.66-7.53(m, 2H), 7.43-7.32(m, 2H), 7.09(t, J=7.4Hz, 1H) , 6.09 (d, J=5.7Hz, 1H), 4.10-3.97 (m, 2H), 3.19-3.09 (m, 1H), 2.89 (s, 2H), 1.9 3(d, J=13.3Hz, 2H), 1.81(s, 3H), 1.78(s, 3H), 1.75-1.64(m, 2H), 1.42(s, 9H).

[0726] Compound 103: Dimethyl(2-((2-((3-(piperidin-4-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)phosphine oxide hydrochloride

[0727] [Reaction 103]

[0728]

[0729] 1) tert-butyl4-(5-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate

[0730] To a solution of compound 20-343 (150 mg, 0.305 mmol) dissolved in dioxane / water (2 ml), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (170 mg, 0.549 mmol) was added, followed by the addition of bistriphenylphosphine palladium dichloride (42.8 mg, 0.061 mmol) and sodium carbonate (97.0 mg, 0.915 mmol). The reaction mixture was heated at 110 ° C for 4 hours using a microwave. TLC showed the formation of new spots, the solid was filtered and the solvent was evaporated under vacuum. For the unpurified mixture, 5% MeOH:DCM was used as a solvent mixture and purified by MPLC to obtain compound 20-346 (176 mg, 0.296 mmol, 72%) as an off-white solid.

[0731] LCMS: 594.1 [M+H]+.

[0732] 1H NMR (400MHz, DMSO-d6) δ12.89 (s, 1H), 11.21 (s, 1H), 9.35 (s, 1H), 8.59 (s, 1H), 8.27-8.14 (m, 2H), 7.62-7.49 (m, 2H), 7.46 (d, J=8.9Hz, 1H), 7.25(s, 1H), 7.08(t, J=7.5Hz, 1H), 6.29(s, 1H), 3.91(s, 2H), 3.61-3 .48(m, 2H), 2.71-2.60(m, 2H), 1.81(s, 3H), 1.78(s, 3H), 1.43(s, 9H).

[0733] 2) tert-butyl 4-(5-((4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)piperidine-1-carboxylate

[0734] Pt / O2 (7.5 mg, 15 mol%) was added to a suspension of compound 20-346 (50.0 mg, 0.0843 mmol) in 0.5 ml of DMF and EtOH (4.5 ml) at room temperature. The resulting mixture was shaken in a parr reactor for 36 hours under a hydrogen atmosphere (50 psi). TLC showed the generation of new spots, and the mixture was filtered through a celite bed and washed with EtOH. The solvent was completely evaporated under vacuum. For the unpurified mixture, 15% MeOH:MC was used as a solvent mixture and purified by MPLC to obtain a purple solid compound 20-362 (7.0 mg, 0.0124 mmol, 14%).

[0735] 1H NMR (500MHz, DMSO-d6) δ12.53 (s, 1H), 10.95 (s, 1H), 9.18 (s, 1H), 8.52 (s, 1H), 8.13-8.02(m, 2H), 7.66-7.53(m, 2H), 7.43-7.32(m, 2H), 7.09(t, J=7.4Hz, 1H) , 6.09 (d, J=5.7Hz, 1H), 4.10-3.97 (m, 2H), 3.19-3.09 (m, 1H), 2.89 (s, 2H), 1.9 3(d, J=13.3Hz, 2H), 1.81(s, 3H), 1.78(s, 3H), 1.75-1.64(m, 2H), 1.42(s, 9H).

[0736] 3)(dimethyl(2-((2-((3-(piperidin-4-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)phosphine oxide hydrochloride)

[0737] To a suspension of compound 20-362 (5.0 mg, 0.0084 mmol) in 1 ml of DCM was added HCl (0.005 ml, 0.020 mmol) at room temperature and stirred for 2 hours. TLC showed that the reaction was complete. The solvent was completely evaporated under vacuum and the residue was washed with diethyl ether to obtain compound 103 (2.6 mg, 0.0050 mmol, 59%) as a hygroscopic purple solid.

[0738] 1H NMR (400MHz, DMSO-d6) δ13.01 (s, 1H), 12.06 (s, 1H), 10.86 (s, 1H), 9.42-8.87 (m, 3H), 7.96 (d, J=45.0Hz, 3H), 7.72 (s, 1H), 7.56 (d, J=8.8Hz, 1H), 7.49-7.12 (m, 3H), 6.37 (d, J=7.2Hz, 1H), 3.42-3.23 (m, 3H), 3.03 (s, 2H), 2.08 (s, 3H), 1.80 (d, J=13.6Hz, 6H).

[0739] Compound 104: (2-((5-Chloro-2-((3-(pyridin-4-yl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0740] [Reaction 104]

[0741]

[0742] To a solution of 20-343 (50.0 mg, 0.102 mmol) in dioxane (5 ml) was added 4-pyridylboronic acid (20.7 mg, 0.122 mmol), followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (32.4 mg, 0.306 mmol). The reaction mixture was heated at 110° C. overnight. TLC showed the formation of a new spot, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 104 (6.10 mg, 0.012 mmol, 12.3%) as a yellow solid.

[0743] 1H NMR (300MHz, Methanol-d4) δ 8.52-8.42 (m, 4H), 8.14 (s, 1H), 7.95-7.90 (m, 5H), 7.56 (d, J=1. 3Hz, 2H), 7.52-7.43(m, 1H), 7.11-7.04(m, 1H), 6.99-6.90(m, 1H), 1.92(s, 3H), 1.88(s, 3H).

[0744] Compound 105: 4-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)benzonitrile

[0745] [Reaction 105]

[0746]

[0747] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in dioxane / water (9:1) (5 ml) was added 4-cyanophenylboronic acid (17.9 mg, 0.122 mmol), followed by addition of bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (32.4 mg, 0.306 mmol). The reaction mixture was heated at 110° C. for 24 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 105 (26.2 mg, 0.051 mmol, 50.0%) as a white solid.

[0748] LC / MS: 514.5 [M+H]+.

[0749] 1H NMR (300MHz, DMSO-d6) δ13.38(s, 1H), 11.23(s, 1H), 9.48(s, 1H), 8.62-8.49(m, 1H), 8.36(s, 1H), 8.25-8.18( m, 3H), 7.83-7.74 (m, 1H), 7.73-7.44 (m, 4H), 7.12-6.85 (m, 2H), 1.82 (d, J=3.5Hz, 3H), 1.77 (d, J=3.5Hz, 3H).

[0750] Compound 106: 1-(4-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)phenyl)ethan-1-one

[0751] [Reaction 106]

[0752]

[0753] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), (4-acetylphenyl)boronic acid (4.4 mg, 0.122 mmol) was added, followed by the addition of bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (32.4 mg, 0.306 mmol). The reaction mixture was heated at 110° C. for 4 hours. TCL showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 106 (28.4 mg, 0.053 mmol, 52.4%) as a yellow solid.

[0754] LC / MS: 531.2 [M+H]+.

[0755] 1H NMR (300MHz, DMSO-d6) δ13.33 (d, J=21.4Hz, 1H), 11.22 (d, J=5.8Hz, 1H), 9.49 (s, 1H), 8 .72-8.39(m, 2H), 8.23(s, 1H), 8.01(q, 2H), 7.93-7.82(m, 1H), 7.71-7.36(m, 4H), 7.18 -7.08 (m, 1H), 6.91 (s, 1H), 2.61 (s, 1H), 1.82 (d, J=3.4Hz, 3H), 1.77 (s, 2H).

[0756] Compound 107: (2-((5-Chloro-2-((3-(3-Chloro-4-fluorophenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0757] [Reaction 107]

[0758]

[0759] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), (3-chloro-4-fluorophenyl)boronic acid (21.3 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110°C for 4 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 107 (3.6 mg, 0.0067 mmol, 6.58%) as a white solid.

[0760] LC / MS: 514.4 [M+H]+.

[0761] 1H NMR (300MHz, DMSO-d6) δ13.29 (s, 1H), 11.24 (d, J = 17.3Hz, 1H), 9.52-9.47 (m, 1H), 8.22 (d, J = 8.1Hz, 1H), 8.04-7.93 (m, 1H), 7.90-7.84 (m , 1H), 7.66 (d, J=9.1Hz, 2H), 7.60 (d, J=7.8Hz, 0H), 7.58-7.39 (m, 3H), 7.15 (t, J=7.6Hz, 1H), 6.99-6.88 (m, 1H), 1.82 (s, 3H), 1.77 (s, 3H).

[0762] Compound 108: (2-((5-Chloro-2-((3-(4-hydroxyphenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0763] [Reaction 108]

[0764]

[0765] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml) was added (4-hydroxyphenyl)boronic acid (16.8 mg, 0.122 mmol), followed by the addition of bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110° C. for 4 hours. TCL showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 108 (18.2 mg, 0.036 mmol, 35.7%) as a white solid.

[0766] LC / MS:505.31[M+H]+.

[0767] 1H NMR (300MHz, DMSO-d6) δ12.92 (s, 1H), 11.17 (s, 1H), 9.56 (s, 1H), 9.36 (s, 1H), 8.57 (s, 1H), 8.19 (s, 2H), 7.77-7.6 6 (m, 2H), 7.65-7.58 (m, 1H), 7.57-7.44 (m, 3H), 7.08-6.97 (m, 1H), 6.84 (d, J=8.5Hz, 2H), 1.81 (s, 3H), 1.76 (s, 3H).

[0768] Compound 109: (2-((5-Chloro-2-((3-(3-fluoro-4-methoxyphenyl)-1H-indazol-5-yl)amino)pyridin-4-yl)amino)phenyl)dimethylphosphine oxide

[0769] [Reaction 109]

[0770]

[0771] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), (3-fluoro-4-methoxyphenyl)boronic acid (20.7 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110° C. for 24 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 109 (17.8 mg, 0.033 mmol, 32.8%) as a white solid.

[0772] LC / MS: 537.17 [M+H]+.

[0773] 1H NMR (300MHz, DMSO-d6) δ13.11 (s, 1H), 11.23 (s, 1H), 9.43 (s, 1H), 8.59 (s, 1H), 8.20 (s, 1H), 8.20 (s, 1H), 7.70 -7.61 (m, 3H), 7.58-7.47 (m, 2H), 7.28-7.15 (m, 2H), 7.06-6.93 (m, 1H), 3.88 (s, 3H), 1.81 (s, 3H), 1.77 (s, 3H).

[0774] Compound 110: (2-((5-Chloro-2-((3-(4-(trifluoromethoxy)phenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide

[0775] [Reaction 110]

[0776]

[0777] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) dissolved in 9:1 dioxane / water (5 ml), (4-(trifluoromethoxy)phenyl)boronic acid (25.1 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110° C. for 24 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 110 (30.9 mg, 0.054 mmol, 53.4%) as a white solid.

[0778] LC / MS: 573.15 [M+H]+.

[0779] 1H NMR (300MHz, DMSO-d6) δ13.26 (s, 1H), 11.24 (s, 1H), 9.45 (s, 1H), 8.64-8.53 (m, 1H), 8.34 (s, 1H), 8.21 (s, 1H), 8.01 ( d, J=8.6Hz, 2H), 7.64 (d, J=9.1Hz, 1H), 7.58-7.46 (m, 2H), 7.42 (d, 2H), 7.17-6.87 (m, 2H), 1.81 (s, 3H), 1.76 (s, 3H).

[0780] Compound 111: (2-((5-Chloro-2-((3-(4-Chloro-3-(trifluoromethyl)phenyl)-1H-indazol-5-yl)amino)pyrimidin-4yl)amino)phenyl)dimethylphosphine oxide

[0781] [Reaction 111]

[0782]

[0783] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), (4-chloro-3-(trifluoromethyl)phenyl)boronic acid (72.1 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110° C. for 4 hours. TLC showed the formation of a new spot, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 111 (29.2 mg, 0.049 mmol, 48.9%) as an off-white solid.

[0784] LC / MS: 591.08 [M+H]+.

[0785] 1H NMR (300MHz, DMSO-d6) δ13.42 (s, 1H), 11.33 (s, 1H), 9.56 (s, 1H), 8.58 (s, 1H), 8.49 (s, 1H), 8.28 (d, J=2.1Hz, 1H), 8.21 (s, 1H) , 8.12 (d, J=8.4Hz, 1H), 7.73-7.61 (m, 2H), 7.60-7.45 (m, 2H), 7.12-6.93 (m, 1H), 6.91-6.79 (m, 1H), 1.83 (s, 3H), 1.79 (s, 3H).

[0786] Compound 112: (2-((5-Chloro-2-((3-(3-Chloro-4-methylphenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0787] [Reaction 112]

[0788]

[0789] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), 3-chloro-4-methylphenyl boronic acid (20.8 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110°C for 4 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 112 (42.2 mg, 0.079 mmol, 77.7%) as an off-white solid.

[0790] LC / MS: 537.24 [M+H]+.

[0791] 1H NMR (300MHz, DMSO-d6) δ13.21 (s, 1H), 11.27 (s, 1H), 9.48 (s, 1H), 8.67-8.53 (m, 1H), 8.20 (s, 1H), 7.90-7.85 (m, 1H), 7.75 (dd, J=7.9, 1.7Hz, 1 H), 7.68-7.60 (m, 2H), 7.60-7.51 (m, 3H), 7.39 (d, J=8.0Hz, 1H), 7.21- 7.05 (m, 1H), 7.00-6.89 (m, 1H), 2.37 (s, 3H), 1.82 (s, 3H), 1.77 (s, 3H).

[0792] Compound 113: (2-((5-Chloro-2-((3-(3-Chloro-5-methoxyphenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0793] [Reaction 113]

[0794]

[0795] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), 3-chloro-5-methoxybenzeneboronic acid (22.7 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110°C for 5 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 113 (22.4 mg, 0.040 mmol, 40%) as a white solid.

[0796] LC / MS: 553.24 [M+H]+.

[0797] 1H NMR (300MHz, DMSO-d6) δ13.29 (s, 1H), 11.25 (d, J=7.7Hz, 1H), 9.49 (s, 1H), 8.62 (s, 1H), 8.35-8.21 (m, 1H), 8.19 (s, 1H), 7.78-7.70 (m , 1H), 7.60-7.47(m, 3H), 7.42-7.37(m, 1H), 7.24-7.11(m, 1H), 7.04-6.97(m, 2H), 3.84(s, 3H), 1.83-1.79(m, 3H), 1.79-1.75(m, 3H).

[0798] Compound 114: (2-((5-Chloro-2-((3-(4-(methylsulfonyl)phenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphineoxide)

[0799] [Reaction 114]

[0800]

[0801] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) dissolved in 9:1 dioxane / water (5 ml), (4-(methyl sulfonyl)phenyl)boronic acid (24.4 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110° C. for 5 hours. TLC showed the formation of a new spot, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 114 (27.9 mg, 0.049 mmol, 49%) as a white solid.

[0802] LC / MS: 567.21 [M+H]+.

[0803] 1H NMR (300MHz, DMSO-d6) δ13.43 (s, 1H), 11.22 (s, 1H), 9.54 (s, 1H), 8.56-8.48 (m, 2H), 8.15-8.06 (m, 2H), 7.95- 7.86 (m, 2H), 7.67-7.53 (m, 3H), 7.55-7.40 (m, 2H), 6.88-6.83 (m, 1H), 3.25 (s, 3H), 1.84 (s, 3H), 1.79 (s, 3H).

[0804] Compound 115: (2-((5-Chloro-2-((3-(3-fluoro-5-isopropoxyphenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0805] [Reaction 115]

[0806]

[0807] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), (3-fluoro-5-isopropoxyphenyl)boronic acid (24.2 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110° C. for 24 hours. TLC showed the formation of a new spot, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 115 (38.1 mg, 0.067 mmol, 0.67%) as an off-white solid.

[0808] LC / MS: 565.26 [M+H]+.

[0809] 1H NMR (300MHz, DMSO-d6) δ13.25 (s, 1H), 11.25 (s, 1H), 9.47 (s, 1H), 8.71 -8.53 (m, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 7.78-7.67 (m, 1H), 7.61-7.48 (m, 2H), 7.27 (s, 1H), 7.20 (d, J=9.6Hz, 2H), 7.07-6.95 (m, 1H), 6.84-6.76 (m, 1H), 4.77-4.65 (m, 1H), 1.81 (s, 3H), 1.76 (s, 3H), 1.31 (d, J=6.0Hz, 6H).

[0810] Compound 116: 3-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)benzonitrile

[0811] [Reaction 116]

[0812]

[0813] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml) was added (3-cyanophenyl)boronic acid (17.9 mg, 0.122 mmol), followed by addition of bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110°C for 24 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 116 (34.2 mg, 0.067 mmol, 66%) as an off-white solid.

[0814] LC / MS: 541.09 [M+H]+.

[0815] 1H NMR (400MHz, DMSO-d6) δ13.39 (s, 1H), 11.33 (s, 1H), 9.55 (s, 1H), 8.55 (s, 1H), 8.36 (d, J = 1.8Hz, 1H), 8.23 ​​(d, J = 10.0Hz, 3H), 7.82-7.76 (m, 1H), 7.71-7.62 (m, 2H), 7.58 (d, J=8.9Hz, 1H), 7.52 (dd, J=14.0, 7.6Hz, 1H), 7.15-6.99 (m, 1H), 6.94 (s, 1H), 1.80 (d, J=13.5Hz, 6H).

[0816] Compound 117: tert-Butyl 4-(4-(5-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1H-indazol-3-yl)phenyl)piperazine-1-carboxylate

[0817] [Reaction 117]

[0818]

[0819] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml) was added 4-(4-Boc-piperazino)phenylboronic acid (37.4 mg, 0.122 mmol), and then bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110° C. for 24 hours. TLC showed the formation of a new spot, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a solvent mixture to obtain compound 117 (37.4 mg, 0.056 mmol, 55%) as an off-white solid.

[0820] LC / MS: 673.33 [M+H]+.

[0821] 1H NMR (300MHz, DMSO-d6) δ12.93 (s, 1H), 11.25 (s, 1H), 9.39 (s, 1H), 8.72-8.53 (m, 1H), 8.28-8.15 (m, 2H), 7.78 (d, J=8.5Hz, 2H), 7.68-7.59 (m , 1H), 7.58-7.51(m, 1H), 7.51-7.46(m, 1H), 7.18-6.96(m, 4H), 3.54-3 .44(m, 4H), 3.22-3.12(m, 4H), 1.81(s, 3H), 1.76(s, 3H), 1.44(s, 9H).

[0822] Compound 118: (2-((5-Chloro-2-((3-(3-hydroxyphenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0823] [Reaction 118]

[0824]

[0825] To a solution of compound 20-343 (50.0 mg, 0.102 mmol) in 9:1 dioxane / water (5 ml), (3-hydroxyphenyl)boronic acid (16.8 mg, 0.122 mmol) was added, followed by bistriphenylphosphine palladium dichloride (14.3 mg, 0.0204 mmol) and sodium carbonate (65.8 mg, 0.202 mmol). The reaction mixture was heated at 110°C for 24 hours. TLC showed the formation of new spots, and the solvent was completely evaporated under vacuum. The residue was purified by MPLC using 10% MeOH:MC as a mixed solvent to obtain compound 118 (18.7 mg, 0.037 mmol, 37%) as a white solid.

[0826] LCMS: 505.2 [M+H]+.

[0827] 1H NMR (400MHz, DMSO-d6) δ13.07 (s, 1H), 11.21 (s, 1H), 9.48 (s, 1H), 8.23-8.17 (m, 2H), 8.09 (d, J=1.2Hz, 1H), 7.73-7.61 (m, 2H), 7.55-7.47 (m, 2H), 7.39-7.31 (m, 2H), 7.25 (t, J=7.8Hz, 1H), 7.22-7.16 (m, 1H), 7.06-6.97 (m, 1H), 6.75 (d, J=8.5Hz, 1H), 1.79 (s, 3H), 1.76 (s, 3H).

[0828] Compound 119: (2-((5-Chloro-2-((3-(4-(piperazin-1-yl)phenyl)-1H-indazol-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

[0829] [Reaction 119]

[0830]

[0831] At room temperature, to a solution of compound 117 (80.0 mg, 0.134 mmol) in 5 ml of DCM, 4N HCl in dioxane (0.083 ml, 0.335 mmol) was added and stirred for 2 hours. TLC showed that the reaction was complete. The solvent was completely evaporated under vacuum. The residue was dissolved in 15 ml of water, washed with DCM (15 ml × 2), and after the aqueous layer was alkalized with sodium bicarbonate powder, DCM (20 ml × 3) was used for extraction. The combined organic layer was dried over sodium sulfate, and the solvent was evaporated under vacuum to obtain compound 119 (56.0 mg, 0.112 mmol, 84%) as an off-white solid.

[0832] 1H NMR (400MHz, DMSO-d6) δ12.92 (s, 1H), 11.23 (s, 1H), 9.39 (s, 1H), 8.61 (s, 1H), 8.28-8.17 (m, 2H), 7.75 (d, J=8.6Hz, 2H), 7.61 (d, J=9 .0Hz, 1H), 7.56-7.46(m, 2H), 7.21-7.07(m, 1H), 7.05-6.94(m, 3H), 3.16-3.02(m, 4H), 2.91-2.79(m, 4H), 1.80(s, 3H), 1.77(s, 3H).

[0833] Example 2. Confirmation of enzyme inhibitory activity and anticancer activity of the compounds of the present invention

[0834] The m1K3 / LRRK2 enzyme inhibitory activity and the anticancer activity in HepG2 / HS746T cancer cells were confirmed using the compounds 1 to 119 of the present invention synthesized in Example 1. The results are shown in Table 1.

[0835] MLK3 and LRRK2 enzyme inhibitory activity was evaluated by Eurofins. Briefly, human recombinant mlK3 protein and the compound were mixed in a reaction solution (8 mM MOPS (pH 7.0), 0.2 mM EDTA, 0.33 mg / mL myelin basic protein, 5 mM DTT), and then a mixture of 10 mM magnesium acetate and γ-32P-ATP (gamma-33P-ATP) was added and allowed to react at room temperature for 120 minutes. Then, 0.5% phosphoric acid was added to terminate the reaction, and 10uL of the entire mixture was spotted on a P30 filter mat, washed with 0.425% phosphoric acid for 4 minutes, a total of 4 times, and washed once with methanol. The activity of MLK3 was measured by scintillation counting and evaluated as a percentage ratio (% value) compared with the control group. Regarding the activity of LRRK2, human recombinant LRRK2 protein was mixed with the compound in a reaction solution (50 mM HEPES (pH 8.0), 0.2 mM EDTA, 0.01% Brij-35, 1% (w / v) bovine serum albumin (BSA), 5 mM dithiothreitol (DTT), 250 uM substrate peptide (RLGRDKYKTLRQIRQ)), and then a mixture of 10 mM magnesium acetate and γ-32P-ATP (gamma-33P-ATP) was added, and the mixture was reacted at room temperature for 40 minutes. Then, 0.5% phosphoric acid was added to terminate the reaction, and 10uL of the entire mixture was spotted on a P30 filter mat, washed with 0.425% phosphoric acid for 4 minutes, a total of 4 times, and washed once with methanol. The activity of LRRK2 was measured by scintillation counting and evaluated as a percentage ratio (%) compared with the control group.

[0836] Anticancer activity was evaluated as follows. HepG2 and HS746T cancer cells were purchased from the Korean Cell Line Bank and cultured according to the provided method. In a 96-well plate, 4000 cells were seeded in each well using 100uL of cell culture medium, treated with the compound after 24 hours, and cell viability was evaluated using CCK-8 after 72 hours, where the percentage ratio (% value) relative to the control group was evaluated.

[0837] [Table 1]

[0838]

[0839]

[0840]

[0841]

[0842] Referring to Table 1 above, the pyrimidine compound of the present invention simultaneously exhibits inhibitory activity against MLK3 and LRRK2 at a concentration of 0.001 to 1 μM, and exhibits excellent anticancer activity in the HepG2 / HS746T cancer cell experiment.

[0843] Therefore, it was confirmed that the compound of the present invention is useful for preventing or treating cancer, viral infectious diseases, Parkinson's disease, nonalcoholic steatohepatitis, and tuberculosis, which are diseases associated with mLK3 and LRRK2 inhibitory activities.

[0844] <Preparation Example 1. Preparation of Powder>

[0845] 2 g of the present compound 10 ((2-((5-chloro-2-((2-methylpyridin-4-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide) and 1 g of lactose were mixed and filled into an airtight packaging bag to prepare a powder.

[0846] <Preparation Example 2. Preparation of Tablets>

[0847] After mixing 100 mg of the compound of the present invention 10 ((2-((5-chloro-2-((2-methylpyridin-4-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide), 100 mg of microcrystalline cellulose, 60 mg of lactose hydrate, 20 mg of low-substituted hydroxypropyl cellulose and 2 mg of magnesium stearate, tablets were prepared by tableting according to a conventional tablet preparation method.

[0848] <Preparation Example 3. Preparation of Capsules>

[0849] After mixing 100 mg of the compound of the present invention 47 (2-((5-chloro-2-((1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide), 100 mg of microcrystalline cellulose, 60 mg of lactose hydrate, 20 mg of low-substituted hydroxypropyl cellulose and 2 mg of magnesium stearate, the above ingredients are mixed and filled in a gelatin capsule according to a conventional capsule preparation method to prepare a capsule.

[0850] <Preparation Example 4. Preparation of Pills>

[0851] After mixing 90 mg of the compound of the present invention 47 (2-((5-chloro-2-((1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide), 5 mg of glutinous rice starch and 5 mg of purified water and a small amount of dextrin, maltodextrin, corn starch, and microcrystalline cellulose (MCC) as known hygroscopic additives, 100 mg of pills were prepared according to the conventional method.

[0852] <Preparation Example 5. Preparation of Injection>

[0853] After mixing 10 mg of the compound of the present invention 47 (2-((5-chloro-2-((1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide), an appropriate amount of sterile distilled water for injection and an appropriate amount of pH adjuster, the mixture is prepared according to the conventional method for preparing injections in accordance with the above-mentioned component contents for each ampoule (2 ml).

Claims

1. A pharmaceutical composition for preventing or treating Parkinson's disease or non-alcoholic steatohepatitis, wherein: Containing a compound represented by the following Chemical Formula 10 or a pharmaceutically acceptable salt thereof as an active ingredient, [Chemical formula 10] In the chemical formula 10, R1 is X is hydrogen or a halogen substituent; R2 is a substituent selected from the group consisting of hydrogen, C1-C4 alkyl or acetyl; R6 is a substituent selected from the group consisting of hydrogen, C1-C6 alkyl, halogenated C1-C6 alkylcarbonyl, trifluoromethylcarbonyl, acetyl, and Boc; R7 is one or more substituents selected from the group consisting of hydrogen, C1-C6 alkyl, halogen, and hydroxyl; n is an integer of 0 or 1; m is an integer of 0, 1 or 2.

2. The pharmaceutical composition for preventing or treating Parkinson's disease or non-alcoholic steatohepatitis according to claim 1, wherein: Contains a compound selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof as an active ingredient: Compound 41: 7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-1(2H)-one; Compound 42: 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1,1-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; Compound 43: 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)(ethyl)amino)-1,1-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; Compound 44: (2-((5-chloro-2-((1,1-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; Compound 45: (2-((5-chloro-2-((2-(5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-5-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; Compound 46: 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; Compound 47: (2-((5-chloro-2-((1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; Compound 48: 1-(6-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; Compound 49: (2-((5-chloro-2-((1,2,3,4-tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; Compound 50: 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4,4-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; Compound 51: (2-((5-chloro-2-((1-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; Compound 52: (2-((5-chloro-2-((4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; Compound 53: 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; Compound 54: 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; Compound 55: (2-((5-chloro-2-((1-isopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; Compound 62: 1-(7-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethane-1-one; and Compound 63: (2-((5-chloro-2-((6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide.